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Wolfram syndrome (OMIM #222300) is a rare hereditary neurodegenerative 
disorder that is caused by biallelic mutations in the WFS1 gene, from which WFS1 
(Wolframin) protein is encoded (Inoue et al., 1998; Strom, 1998). Wolfram 
syndrome prevalence varies worldwide, the highest prevalence has been reported 
in Lebanon (1 in 68 000 people) and the lowest in the United Kingdom (1 in 
770 000 people) (Kumar, 2010). The first symptom of Wolfram syndrome is 
diabetes mellitus, followed by optic nerve atrophy, diabetes insipidus, deafness 
and progressive brainstem atrophy (Barrett et al., 1995). The inferior olive and 
other medullary nuclei induce most of the Wolfram syndrome patients’ clinical 
neurological features (Hilson et al., 2009). 
Currently, there is no cure for Wolfram syndrome, and only supportive treat-
ment is used to relieve the symptoms (Urano, 2016). New treatment strategies for 
Wolfram syndrome should be directed toward finding prevention and treatment 
options for both Wolfram syndrome symptoms: diabetes mellitus and neuro-
degeneration. Diabetes mellitus can effectively be controlled with insulin replace-
ment therapy; therefore, for Wolfram syndrome patients, it is most important to 
find a neuroprotective therapy that can prevent or delay brainstem neuro-
degeneration and thereby significantly improve quality of life. As no effective 
therapy is available, drug repurposing could be the best therapeutic option 
because the drugs are already approved and thus reach patients faster (Pallotta et 
al., 2019).  
GLP-1 receptor agonists are used for the treatment of diabetes mellitus and 
have neuroprotective properties in addition to glucose-lowering effects. Hence, 
they could also have a potential therapeutic effect for the main symptoms of 
Wolfram syndrome. In addition to GLP-1 receptor agonists, the neurotrophic 
factor, such as brain-derived neurotrophic factor (BDNF) mimetic 7,8-di-
hydroxyflavone (7,8-DHF), has not been studied in connection with Wolfram 
syndrome. In vivo investigations for drug repurposing would not be possible 
without well-characterized animal models. Therefore, our research group has 
created Wfs1 KO rats with an exon 5 disruption. The aim of this dissertation is 
(i) to evaluate the symptoms of Wolfram syndrome in Wfs1 KO rats and (ii) to 
use it to test novel treatment strategies for Wolfram syndrome with an emphasis 
on neurodegeneration.  
The current thesis demonstrates that Wfs1 KO rats developed the main 
symptoms of Wolfram syndrome: diabetes mellitus and neurodegeneration. This 
indicates that the Wfs1 KO rat is indeed a Wolfram syndrome animal model, and 
it can be used to test treatment strategies for Wolfram syndrome. The anti-
diabetic drug liraglutide protected Wfs1 KO rats against development of glucose 
intolerance. Moreover, liraglutide treatment had a neuroprotective effect in the 
olive nucleus, as measured by decreased neuroinflammation, ER stress and neu-
ronal swelling. Additionally, BDNF mimetic 7,8-DHF had an anti-inflammatory 
effect on the hippocampus and maintained cognitive function in Wfs1 KO 
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animals. However, an anti-diabetic effect of 7,8-DHF was not detected. There-
fore, liraglutide treatment alone or co-treatment with liraglutide and 7,8-DHF 
could be promising treatment strategies for Wolfram syndrome patients. Inspired 
by preclinical studies, a liraglutide clinical trial has been initiated, and further 
investigations will clarify the effect of liraglutide in Wolfram syndrome patients.  
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2 REVIEW OF LITERATURE 
2.1 Clinical manifestation of Wolfram syndrome 
The schematic representation of Wolfram syndrome clinical symptoms is seen 
in Figure 1. The first symptom of Wolfram syndrome is non-autoimmune, insulin-
dependent diabetes mellitus that is diagnosed around the age of six years (Rigoli 
et al., 2018). Compared to type 1 diabetes, Wolfram syndrome patients have lower 
insulin requirements and glycated hemoglobin levels (Cano et al., 2007). 
Additionally, Wolfram syndrome patients’ insulinopenia is caused due to the 
degeneration of pancreatic beta cells, in which WFS1 is widely expressed, and 
not from autoimmune destruction of pancreatic beta cells (Cano et al., 2007).  
The second symptom required for the diagnosis of Wolfram syndrome is optic 
nerve atrophy, which appears around the age of 11 years (Kumar, 2010). Optic 
nerve atrophy is characterized by a progressive decrease in visual acuity due to 
the development of cataracts, abnormal papillary light reflexes, nystagmus, glau-
coma, and pigmentary maculopathy (Pallotta et al., 2019). Diabetes insipidus 
caused by vasopressin deficiency appears around the age of 14 years and the 
average age of hearing loss diagnosis is 16 years (Kumar, 2010). 
Mental impairment with psychomotor delay and learning difficulties are 
mainly found in Wolfram syndrome patients who developed neurological symp-
toms before the age of 15 years (Chaussenot et al., 2011). Bischoff et al. com-
pared genetically confirmed Wolfram syndrome patients to age- and gender- 
equivalent groups of individuals with type 1 diabetes and with healthy controls 
and found, by contrast, that cognitive performance and psychological health were 
relatively preserved in Wolfram syndrome patients. They concluded that cogni-
tive and psychiatric issues might become more prominent later in life (Bischoff 
et al., 2015). Reduced cognitive function is strongly correlated with hippocampal 
shrinkage (Apostolova et al., 2012), although hippocampal atrophy is not detected 
in Wolfram syndrome patients (Hershey et al., 2012; Hilson et al., 2009; Lugar 
et al., 2016). Additionally, cognitive decline correlates with ventricular volume 
increase (Carmichael et al., 2007), which has been reported in connection with 
aging (Hamezah et al., 2017) and neurodegeneration (Carmichael et al., 2007). 
Mildly dilated lateral ventricles also have been described in one Wolfram syndrome 
patient’s post-mortem study (Shannon et al., 1999), and additionally, mild third 
ventricle enlargement was also reported in Wolfram syndrome patients during an 
MRI study (La Morgia et al., 2020).  
Progressive brainstem neurodegeneration is considered to be a common 
feature of Wolfram syndrome, and the most frequently described symptoms caused 
by it are gait and balance abnormalities, dysphagia, decreased ability to taste and 
Wolfram syndrome is diagnosed by (i) juvenile onset diabetes mellitus and by 
(ii) juvenile onset optic atrophy, and the diagnosis is confirmed by genetic testing 
to identify autosomal recessive mutations in the WFS1 gene (Urano, 2016). 
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detect odours, and central apnea (Pallotta et al., 2019). Before quantitative neuro-
imaging, brainstem atrophy was detected by visual examination of MRI images 
or from post-mortem macroscopic examination. Thus, the data was obtained from 
individuals in the relatively late stage of the disease or from case studies without 
quantification or comparison with a control group. Modern in vivo brain quanti-
tative neuroimaging is a powerful, non-invasive method to investigate histo-
pathological abnormalities without the need for post-mortem tissue. Quantitative 
neuroimaging allows repetitive measurements and longitudinal studies in which 
changes of volume are monitored over time (Samara et al., 2019). Quantitative 
neuroimaging studies from genetically confirmed groups of Wolfram syndrome 
patients have revealed decreased brainstem volumes in almost all Wolfram 
syndrome patients regardless of age or duration of diabetes or other features of the 
disease (Hershey et al., 2012; Lugar et al., 2016). Additionally, Wolfram syndrome 
patients’ brainstem volume decreased with age, whereas the volume usually 
increases in healthy controls (Lugar et al., 2019). Altogether, the prognosis of 
Wolfram syndrome is currently poor, and without treatment, patients die prema-
turely due to brainstem atrophy induced respiratory failure in their 30s (Urano, 
2016).  
 
Figure 1. Temporal manifestation of Wolfram syndrome clinical symptoms. The first 
symptom of Wolfram syndrome is diabetes mellitus, followed by optic nerve atrophy, 
diabetes insipidus, hearing loss and progressive brainstem neurodegeneration. Figure is 





2.2 Olive nucleus pathology in Wolfram syndrome  
Wolfram syndrome includes phenotypical manifestations of olivopontocerebellar 
atrophy (Leiva-Santana et al., 1993). Hence, it is suggested that the pathology of 
the inferior olive and other medullary nuclei produce most of the Wolfram 
syndrome patients’ clinical neurological features (Hilson et al., 2009). The olive 
nucleus consists of three sub-nuclei: the medial nucleus, dorsal nucleus and 
principal nucleus, and is mostly associated with integrating motor and sensory 
information (Paul and M Das, 2019). Additionally, the inferior olive has a role in 
the central sympathetic functions and may also be involved in functional inter-
actions between the motor and thermoregulatory systems, such as an increase in 
body temperature, convulsions and shivering (Uno and Shibata, 2001). 
Olive nucleus pathology has been described in several Wolfram syndrome 
patients through post-mortem macroscopic examinations. Genís et al. reported 
post-mortem findings on a Wolfram syndrome patient who died at the age of 37 
years because of food aspiration. They described the patient’s mild olivo-
pontocerebellar atrophy, moderate loss of neurons in the inferior olive and mild 
loss of motor neurons in the spinal cord accompanied by mild gliosis, as revealed 
in sections that were immunostained for Glial fibrillary acidic protein (GFAP). 
Additionally, a few of the remaining Purkinje cells showed axonal ballooning 
(Genís et al., 1997). 
In a post-mortem macroscopic study of a 38-year-old female Wolfram syn-
drome patient, Shannon et al. noted atrophy of the medulla and axonal swelling 
in the pontocerebellar tracts and in the inferior olive. Additionally, chromatolytic 
neurons were noted in the pons, where neuronal cell loss was undetectable (Shan-
non et al., 1999). This suggests that neuronal swelling and chromatolysis might 
proceed to neuronal loss. 
Moreover, one Wolfram syndrome patient who succumbed to complications 
of adult respiratory distress syndrome at the age of 24 years had lost about 60% 
of the inferior olive neurons in a diffuse pattern (Hilson et al., 2009). 
Taken together, these results indicate that olive nucleus neurodegeneration 




2.3 WFS1 and ER stress in Wolfram syndrome 
The Wolfram syndrome causing gene – WFS1 gene was identified by two inde-
pendent research groups in 1998 (Inoue et al., 1998; Strom et al., 1998). From 
WFS1 gene, WFS1 protein is encoded (Wolframin) which consists of 890 amino 
acids and has a molecular mass of 100 kDa (Inoue et al., 1998). WFS1 protein is 
highly expressed throughout the brain and in the heart, and pancreas (Hofmann, 
2003). Subcellularly, WFS1 protein localizes primary in the endoplasmic reticulum 
(ER) membrane (Takeda, 2001), where it modulates Ca2+ concentration and 
thereby has an important role in the ER homeostasis (Takei et al., 2006). 
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Mutations in the WFS1 gene result in decreased or deficient WFS1 protein 
function, leading to the impairment of cellular calcium regulation and, thereby, 
to accumulation of unfolded proteins in the ER, a condition known as ER stress, 
which in turn activates the unfolded protein response (UPR) (Urano, 2016). 
A schematic representation of UPR pathways is seen in Figure 2. The aim of UPR 
pathways is to restore ER homeostasis through reducing the protein load in the 
ER and decreasing protein translation. Three transmembrane proteins mediate the 
UPR signal across the ER membrane: inositol-requiring enzyme 1 (IRE1), 
eukaryotic translation initiation factor 2α (eIF2α) kinase 3 (PERK) and activating 
transcription factor 6 (ATF6). In the physiological state, ATF6, IRE1 and PERK 
activity is suppressed because they are associated with glucose-regulated protein 
78 (GRP78, also known as BIP). Under ER stress, unfolded proteins accumulate 
in the ER lumen, causing GRP78 to dissociate from ATF6, IRE1 and PERK, 
which causes their homodimerization, autophosphorylation and activation of 
cytoprotective downstream pathways (Lee, 2005). However, when cell survival 
is not anymore possible, excessive stress leads to the activation of C/EBP homo-
logous protein (CHOP) apoptosis pathway (Figure 2) (Zinszner et al., 1998).  
Figure 2. The UPR pathway. The UPR pathway’s aim is to restore ER homeostasis. Three 
transmembrane proteins mediate the UPR signal across the ER membrane: ATF6, IRE1 
and PERK. Figure is prepared according to (Jakobsen et al., 2008; Timberlake and 




WFS1 plays a key role in ER stress in beta-cells. WFS1 is a component of IRE1 
and PERK signaling (Fonseca et al., 2005) and it negatively regulates ATF6. WFS1 
dysfunction leads to chronic hyperactivation of ATF6 signalling, which is 
involved in apoptosis through apoptotic effectors of the UPR, such as CHOP 
(Fonseca et al., 2010). 
ER stress can also induce excitotoxicity due to persistent glutamate receptor 
overstimulation, which can lead to cell apoptosis (Sokka et al., 2007). It has also 
been shown that GRP78 is able to suppress ER stress and thereby can protect 
neurons against glutamate-induced excitotoxicity (Yu et al., 1999). 
In addition to the pathogenesis of diabetes, ER stress is a major cause of neuro-
degeneration in aging and in different neurodegenerative diseases, such as in 
Alzheimer’s disease, Parkinson’s disease and Amyotrophic Lateral Sclerosis (Lee, 
2005). 
In conclusion, ER stress plays an important role in the development of the 
main symptoms of Wolfram syndrome: diabetes and neurodegeneration. There-




2.4 Neuroinflammation in neurodegeneration  
Neuroinflammation is an inflammatory response within the brain and is mediated 
by the production of cytokines, chemokines, reactive oxygen species, and secon-
dary messengers. These mediators are mainly produced by microglia and astroglia 
to maintain cellular homeostasis (DiSabato et al., 2016). 
Microglia are myeloid-origin innate immune cells that express CX3CR1, 
CD11B, IBA1, and F4/80 (Ransohoff and Khoury, 2016). Microglia cells are 
constantly engaged because they are involved in three essential functions: 
(i) sensing their environment, (ii) conducting physiological housekeeping, and 
(iii) protecting against modified-self and non-self-injurious agents. For example, 
microglia failure to clean up debris and misfolded proteins can cause Aβ accumu-
lation in Alzheimer’s disease and α-synuclein accumulation in Parkinson’s 
disease (Halliday and Stevens, 2011; Hickman et al., 2008). Dysregulation of any 
of these functions results in an imbalance that initiates or propagates neuro-
degeneration (Hickman et al., 2018).  
Astroglia cells provide trophic, metabolic, and structural support for neurons 
and play an active role in complex neuronal‐glial communication, synaptic sig-
nalling and regulation of blood flow (Seifert et al., 2006). Similarly to microglia 
cells, astroglia dysfunction can aggravate Aβ plague formation in Alzheimer’s 
disease (Pihlaja et al., 2011) and pathophysiology in Parkinson’s disease (Booth 
et al., 2017). Mild astrogliosis has also been detected in Wolfram syndrome 
patients (Genís et al., 1997; Shannon et al., 1999). However, neuroinflammation 
has not been studied in detail in connection with Wolfram syndrome. 
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Taken together, pathological chronic neuroinflammation implies that glial cell 
activation precedes and causes neuronal degeneration in chronic neurodegene-
rative diseases. Therefore, neuroinflammation could be the therapeutic target for 
neurodegenerative diseases. However experimental models of neurodegeneration 
fail to model neuroinflammation because glial cell activation occurs secondarily 
to neuronal damage (Streit et al., 2004). Hence, animal models in which neuro-




2.5 Neurons and beta cells  
WFS1 is highly expressed in the human adult pancreas and in the brain (Inoue et 
al., 1998), and therefore, pancreatic beta cells and neurons are both affected in 
Wolfram syndrome. Pancreatic beta cells and neurons are in constant demand for 
protein synthesis and secretion. Similarly to neurons, pancreatic beta cells have 
high hormone and enzyme secretory functions and have highly developed ER 
(Thakur et al., 2018). Also, the UPR is classically linked to the maintenance of 
cellular homeostasis in specialized secretory cells, such as pancreatic cells and 
neurons (Thakur et al., 2018). Neurons and pancreatic beta cells share similar 
characteristics, although they are not derived from a common tissue, and they are 
not developed from the same embryonic germ layer (Arntfield and van der Kooy, 
2011). It has been shown that 15% of conserved beta cell markers are also 
expressed in neuronal tissue coding for proteins that are involved in neuro-
transmitter transport, synaptic vesicle formation and brain development (Martens 
et al., 2011). Additionally, the central nervous system major neurotransmitter, 
gamma amino butyric acid (GABA) (Kittler and Moss, 2003), is also produced 
by pancreatic beta cells (Adeghate and Ponery, 2002). GABA is a strong secre-
tagogue of insulin in the pancreas, and the number of GABA-like immuno-
reactive cells is significantly reduced in diabetes (Adeghate and Ponery, 2002). 
Moreover, it has been shown that treatment with GABA has a protective and 
regenerative effect on pancreatic beta cells and thereby is able to reverse type 1 
diabetes (Soltani et al., 2011). Thus, the study of common principles in neurons 
and pancreatic beta cells may provide a basis for prevention and treatment options 
for both Wolfram syndrome symptoms: diabetes mellitus and neurodegeneration. 
 
 
2.6 Treatment strategies for Wolfram syndrome 
It is essential to develop treatment strategies that are able to slow the progression 
of Wolfram syndrome and thereby extend life expectancy. Drug repurposing 
could be the best therapeutic option because of its fast translation into clinical 




2.6.1 Diabetes drugs 
2.6.1.1 Pioglitazone 
Pioglitazone is used to treat type 2 diabetes in adults, particularly in those who are 
overweight. Pioglitazone is a selective agonist of peroxisome proliferator-activated 
receptor-gamma (PPARγ), which is expressed in adipose tissue, skeletal muscle, 
liver (Tyagi et al., 2011) and in the brain (Stump et al., 2016). PPARγ activation 
leads to an improved insulin sensitivity without an increase in insulin secretion 
(Janani and Ranjitha Kumari, 2015). Pioglitazone treatment has been performed 
in Wfs1-deficient mice who developed selective beta cell loss and severe insulin-
deficient diabetes as early as 8 weeks. 20-week treatment with pioglitazone pro-
tected beta cells from apoptosis and almost completely prevented diabetes 
development. It was suggested that the therapeutic effect of pioglitazone was 
caused by reduced ER stress in pancreatic beta cells, although the precise 
mechanisms are not fully understood (Akiyama et al., 2009). Additionally, in a 
mice model of Alzheimer’s disease, pioglitazone has been shown to reduce the 
numbers of activated microglia and Aβ deposition in the brain (Heneka et al., 
2005). Moreover, a pilot study on patients with Alzheimer’s disease demonstrated 
that pioglitazone resulted in cognitive and metabolic improvements (Hanyu et al., 
2009). However, the neuroprotective effect of pioglitazone has not been studied 
in connection with Wolfram syndrome. 
 
2.6.1.2 Glipizide 
Glipizide is a sulphonylurea that acts on the sulfonylurea receptor (SUR1) which 
is expressed in the pancreatic beta cells and in the brain (Guiot et al., 2007). SUR1 
activations cause closure of K-ATP channel which results in cell depolarization, 
opening of the voltage-gated calcium channels and promoting calcium ion influx. 
The increased flow of calcium is causing insulin secretion from the pancreatic 
beta cells and thereby is increasing the plasma concentrations of insulin (Sola et 
al., 2015). Hence, it is an effective glucose-lowering agent used to treat type 2 
diabetes. Also, glipizide’s neuroprotective effect has been shown in the mouse 
hippocampus, and it appears to be mediated by lowering the blood glucose level 
(Kim et al., 2014). However, acute treatment with glipizide was not anti-
hyperglycaemic in Wfs1-deficient mice (Sedman et al., 2016).  
 
2.6.1.3 GLP-1 receptor agonists 
Glucagon-like peptide-1 (GLP-1) is an incretin that is released from the gut after 
a meal to increase glucose-dependent insulin secretion, slow gastric emptying and 
inhibit food intake. These antidiabetic effects make GLP-1 suitable for the 
treatment of type 2 diabetes mellitus. GLP-1 has a very short half-life (1.5–5 min), 
hence, its use in the clinical setting is limited (Müller et al., 2019). Therefore, 
GLP-1 analogues with a longer half-life have been created and can be used as an 
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anti-diabetic treatment. Currently, there are seven GLP-1 receptor agonists that 
are approved by the EMA (European Medicines Agency): short-acting exenatide 
and lixisenatide and long-acting liraglutide, exenatide, dulaglutide, and sema-
glutide. All previously mentioned GLP-1 analogues are administered sub-
cutaneously; the first orally administered GLP-1 analogue is semaglutide tablet 
for once-daily oral use (Table 1) (Trujillo et al., 2021).  
GLP-1 acts on the GLP-1 receptor that is expressed on the pancreatic beta cells 
and throughout the brain on neurons (Baggio and Drucker, 2014), astroglia cells 
(Reiner et al., 2016) and microglia cells (Spielman et al., 2017). GLP-1 receptor 
activation leads to an increase of intracellular cAMP, which then activates protein 
kinase A (PKA), and phosphoinositide 3-kinase (PI3K). After PI3K activation, 
different downstream signalling pathways are activated, which are involved in 
promoting cellular proliferation, inhibition of ER stress, oxidative stress, 
apoptosis, inflammation and protein aggregation (Athauda and Foltynie, 2016). 
Such cytoprotective properties could also be beneficial in the treatment of neuro-
degenerative diseases because diabetes mellitus and neurodegenerative diseases 
share common pathophysiological features, such as cellular stress, inflammation, 
insulin resistance and abnormal protein processing (Salcedo et al., 2012).  
Of the previously listed GLP-1 receptor agonists, liraglutide has the highest 
homology (97% amino acid homology) to native GLP-1 and is also able to cross 
the blood-brain barrier (Hunter and Hölscher, 2012). For these reasons, the 
neuroprotective role of liraglutide has been studied in different neurodegenerative 
diseases, such as in animal models of stroke (Sato et al., 2013), Alzheimer’s disease 
(Hansen et al., 2016) and Parkinson’s disease (Liu et al., 2015). 
From the above, it can be suggested that neuroprotective drugs used for diabetes 
mellitus could also possibly provide an effective treatment option for Wolfram 
syndrome. Exenatide’s antihyperglycaemic effect has been shown in Wfs1-
deficient mice (Sedman et al., 2016). However, the neuroprotective effect of GLP-
1 receptor agonists has not been studied in connection with Wolfram syndrome. 
 
Table 1. GLP-1 receptor agonists currently approved by the EMA (European Medicines 
Agency). Table is prepared according to (Trujillo et al., 2021).  
  Drug 
First approved 
in Europe Dose Half life 
1 Exenatide (Byetta) 2006 5–10 µg twice daily 2.4 h 
2 Lixisenatide (Adlyxin, Lyxumia) 2013 10–20 µg once daily 3 h 
3 Liraglutide (Victoza) 2009 0.6–1.8 mg once daily 13 h 
4 Exenatide (Bydureon) 2011 2 mg once weekly not reported 
5 Dulaglutide (Trulicity) 2014
0.75–1.5 mg once 
weekly 5 days 
6 Semaglutide (Ozempic) 2018
0.25–1 mg once 
weekly 1 week 
7 Oral Semaglutide (Rybelsus) 2020 3–14 mg once daily 1 week 
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2.6.2 BDNF mimetic 7,8-DHF 
Brain-derived neurotrophic factor (BDNF) is a neurotrophin that binds to 
Tropomycin receptor kinase B (TRKB) receptor and regulates neuronal develop-
ment, synaptic function and synaptic plasticity, and modulates neuronal survival 
(Huang and Reichardt, 2001). In addition to BDNF’s neuronal roles, it is also 
important in regulating global metabolic function (Cai et al., 2012). BDNF con-
ditional mutant mice developed obesity and had elevated serum levels of leptin, 
insulin, glucose, and cholesterol (Rios et al., 2001). In humans, mutation of NTRK2, 
which encodes TRKB, results in a unique human syndrome of hyperphagic 
obesity and global developmental delay with specific impairment of short-term 
memory, stereotyped behaviours, and impaired nociception (Yeo et al., 2004). 
BDNF levels significantly decrease with age, which is associated with increased 
risk for cardiovascular disease and metabolic syndrome (Golden et al., 2010).  
 
 
2.6.3 Ongoing clinical trials for Wolfram syndrome 
2.6.3.1 Dantrolene 
Dantrolene is a skeletal muscle relaxant and it is used for the treatment of malignant 
hyperthermia, which is a life threatening genetic sensitivity of skeletal muscles 
to volatile anaesthetics and to depolarizing neuromuscular blocking drugs 
occurring during or after anaesthesia (Krause et al., 2004; Mh, 1975). Dantrolene, 
an inhibitor of RYR1 and RYR2 (Oo et al., 2015), stabilizes ER calcium levels 
and thereby also provides neuroprotection in in vivo models of ischemia (Wei and 
Perry, 2002), epileptic seizures (Mikami et al., 2016) and spinal cord injury 
(Thorell et al., 2002). It has been demonstrated that dantrolene can prevent ER 
stress-mediated cell death in human and rodent Wolfram syndrome cell models. 
Moreover, 4-week dantrolene treatment suppressed calpain activation in brain 
lysates from Wfs1-deficient mice. Thus, it was concluded that dantrolene and 
other drugs that regulate ER calcium homeostasis could be used for the treatment 
of Wolfram syndrome and other diseases associated with ER dysfunction (Lu 
et al., 2014). Inspired by the previously mentioned results, a clinical trial of 
dantrolene in paediatric and adult patients with Wolfram syndrome was started in 
January 2017 in St. Louis, MO, USA, although its effectiveness and safety are 
still unknown (ClinicalTrials.gov: NCT02829268).  
BDNF use is limited in clinical practice mostly because of its inability to cross 
the blood-brain barrier (Poduslo and Curran, 1996). Therefore, small molecules 
acting as BDNF mimetics have been investigated, and the naturally occurring 
flavone 7,8-dihydroxyflavone (7,8-DHF) was found acting as a TRKB receptor 
agonist (Jang et al., 2010). In vivo 7,8-DHF is able to improve spatial learning 
and memory in cognitively impaired aged rats (Zeng et al., 2012) and prevent 
synaptic loss and memory deficits in a mouse model of Alzheimer’s disease (Zhang 
et al., 2014). Additionally, in vitro 7,8-DHF reduces fat production and fat build-




Valproate is used as an antiepileptic drug, although its mechanism of action is 
still a matter of debate. Valproate can act via increasing the GABA concentration 
by reducing its degradation, blocking voltage-gated ion channels, and also by 
inhibiting histone deacetylase (Löscher, 2002; Rahman and Nguyen, 2020). 
Additionally, valproate inhibits ER stress-induced apoptosis and thereby has a 
neuroprotective effect (Kakiuchi et al., 2009). In Wfs1-deficient mice, it has been 
shown that acute treatment with valproate is effective in lowering blood glucose 
levels, possibly by potentiating insulin action (Terasmaa et al., 2011); however, 
chronic treatment with valproate for 3 months had no effect on glucose tolerance 
(Punapart et al., 2014). Nevertheless, a clinical trial of valproate in paediatric and 
adult patients with Wolfram syndrome was initiated in December 2018 in 
Birmingham, UK, and the efficacy, safety and tolerability of valproate are still 
unknown (ClinicalTrials.gov: NCT03717909). 
 
 
2.7 Animal models for studying Wolfram syndrome 
Well-characterized Wolfram syndrome animal models are essential to develop 
treatment strategies for Wolfram syndrome in vivo. Wfs1-deficient mouse models 
have mainly been used to study diabetes mellitus as the mice developed glucose 
intolerance (Ishihara, 2004; Riggs et al., 2005). Additionally, Wfs1-deficient 
mice have been used to describe WFS1 localization in the brain (Luuk et al., 
2008) and to study the role of WFS1 in the development of mood disorders (Luuk 
et al., 2009). However, these animal models have not been studied systematically, 
and the main emphasis has been on diabetes. Relatively few studies have focused 
on neurodegeneration, and no systematic evaluation of all Wolfram syndrome 
symptoms has been done up to now. Thus, a more systematic approach is needed 
to better understand how far the Wolfram syndrome pathology develops in 
Wolfram syndrome animal models and how the phenotype correlates with 
Wolfram syndrome patients. To fill in the gap, our research group has created the 
Wfs1 KO rat. Rats have many advantages over mice for conducting physiological 
and neuroscience studies. The larger size of the rat offers experimental advan-
tages, such as the possibility of repeated blood sampling, better anatomical 
resolution in MRI and more material for biochemical analysis (Iannaccone and 
Jacob, 2009).  
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3 AIMS OF THE STUDY 
As there is no cure for Wolfram syndrome, animal models are needed to test the 
treatment options. WFS1 protein is expressed mostly in the brain and pancreas, 
which share many common features, and investigating the shared part might help 
in finding a treatment for Wolfram syndrome. GLP-1 receptor agonists and neuro-
trophic factors are potential cures for Wolfram syndrome. So far, all preclinical 
treatments have been done in mice, hence the aim of this thesis was to systemati-
cally characterize the Wolfram syndrome rat and use it for the evaluation of novel 
treatment strategies.  
 
Specifically, the aims of this study are: 
 
1. To evaluate the symptoms of Wolfram syndrome in Wfs1 KO rats. 
 
2. To investigate if early intervention with liraglutide has a preventive effect on 
the progression of glucose intolerance in a rat model of Wolfram syndrome. 
 
3. To investigate if late intervention with GLP-1 receptor agonist liraglutide has 
a neuroprotective effect and can thereby prevent the progression of inferior 
olive neurodegeneration in a rat model of Wolfram syndrome. 
 
4. To investigate if liraglutide has a protective effect on the hippocampus as we 
have seen in the pancreas and in the brainstem and if 7,8-DHF alone or in 
combination with liraglutide has a neuroprotective effect on the hippocampus 
in a rat model of Wolfram syndrome. 
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4 MATERIALS AND METHODS 
4.1 Experimental animals (Paper I, II, III, IV) 
Generation of the Wfs1 KO rat line is described in Plaas et al. 2017. Briefly, exon 
5 of Wfs1 gene was deleted using zinc-finger technology, resulting in a loss of 
27 aa from the WFS1 protein sequence (aa 212–238) and a substitution of serine 
to alanine at position 239. Breeding and genotyping of Wfs1 exon 5 knock-out 
Sprague-Dawley rats (Wfs1 KO) were performed at the University of Tartu 
Laboratory Animal Centre. Rats were housed in cages in groups of 2 to 4 rats per 
cage under a 12-h light/dark cycle (lights on at 7 am). Only male rats were used. 
Rats had unlimited access to food and water except during testing. Sniff universal 
mouse and rat maintenance diet (Sniff cat# V1534) and reverse osmosis-purified 
water were used. Experiments were performed between 9 am and 5 pm. All 
experimental protocols were approved by the Estonian Project Authorisation 
Committee for Animal Experiments (No. 54, 23th of February 2015, Paper I), 
(No 103, 22nd of May 2017, Paper II and III), (No 155, 6th of January 2020, 
Paper IV), and all experiments were performed in accordance with the European 
Communities Directive of September 2010 (2010/63/EU) (Plaas et al., 2017; 
Seppa et al., 2019, 2021; Toots et al., 2018). 
 
 
4.2 Animal experiments 
4.2.1 Chronic liraglutide treatment (Paper II) 
The rats were 2 months old at the beginning of the experiment. After the first 
IPGTT test, the rats were randomly allocated into the liraglutide or control groups 
(WT Sal, n = 15; WT Lira, n = 12; KO Sal, n=15; KO Lira, n=13). The liraglutide 
group animals received 0.4 mg/kg liraglutide (Novo Nordisk, Denmark), and the 
control group animals received a 0.9% saline solution subcutaneously. Injections 
of 1 ml/kg volume were made once a day between 8 and 11 am (or immediately 
after a glucose/insulin tolerance test). Rats were weighed once a week. Glucose 
tolerance and insulin tolerance tests were performed 24 hours after the previous 
liraglutide/saline injection. After 5 months of treatment, the rats were euthanized 
(Toots et al., 2018). 
 
 
4.2.2 Chronic liraglutide treatment (Paper III) 
The rats were 8 months old at the beginning of the experiment. Rats were randomly 
allocated into the liraglutide or control groups (WT Sal, n = 8; WT Lira, n = 10; 
KO Sal, n=6; KO Lira, n=8). The liraglutide group animals received 0.4 mg/kg 
liraglutide (Novo Nordisk, Denmark), and the control group animals received a 
0.9% saline solution subcutaneously for 6 months. Injections of 1 ml/kg volume 
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their base blood sugar level was measured once a month from the tail vein using a 
handheld glucometer (Accu-Check Go, Roche, Germany) (Seppa et al., 2019). 
 
 
4.2.3 Chronic liraglutide and 7,8-DHF treatment (Paper IV) 
 
4.2.4 Intraperitoneal glucose tolerance tests (IPGTT) (Paper I, II) 
Animals were deprived of food for 3 h before and during the experiment; water 
was available throughout the experiment. D-Glucose (Sigma-Aldrich) was dis-
solved in a 0.9% saline solution (20% w/vol) and administered intraperitoneally 
at a dose of 2 g/kg of body weight. Blood glucose levels were measured from the 
tail vein using a handheld glucometer (Accu-Check Go, Roche, Germany) before 
glucose administration and at the time points 30 min, 60 min, 120 min and 180 min 
after glucose administration. Blood samples were drawn and collected from the 
tail vein before and 30 min after glucose administration for further analyses (Plaas 
et al., 2017; Seppa et al., 2019; Toots et al., 2018). 
 
4.2.5 In vivo magnetic resonance imaging (Paper I, III, IV) 
Rats were anaesthetized using isoflurane (1.5–2.5% in 1.5 l/min medical oxygen) 
and placed on a heated animal bed throughout the MRI procedure. All scans were 
were made once a day between 8 and 11 am. Rats were weighed once a week, and 
The rats were 9 months old at the beginning of the experiment. Rats were 
randomly allocated into eight experimental groups: (WT Sal, n = 5; WT Lira, 
n = 5; WT Dhf, n= 5; WT Lira+Dhf, n=6; KO Sal, n=6; KO Lira, n=7; KO Dhf, 
n=7; KO Lira+Dhf, n= 8). Saline-treated animals served as control animals. 
Drugs were administered once a day between 8 and 11 am. Rats were weighed 
once a week, and their base blood sugar level was measured once a month from 
the tail vein using a handheld glucometer (Accu-Check Go, Roche, Germany). 
Liraglutide (Lira) from commercially available pens (NovaNordisk) was diluted 
with 0.9% saline and injected s.c. at a dose of 0.4 mg/kg. Saline was administered 
in a volume of 1ml/kg. BDNF mimetic 7,8-dihydroxyflavone (7,8-DHF, catalog 
#D1916, Tokyo Chemical Industry CO Ltd, Tokyo, Japan) was first dissolved in 
DMSO (at a concentration of 400 mg/ml) and was further diluted 1:20 with PEG-
300/PBS mix (1:1). The final composition of the 7,8-DHF injection solution was 
20 mg/ml 7,8-DHF in 5% DMSO, 47.5% PEG-300, 47.5%PBS. The drug or the 
saline solution was administered subcutaneously in a volume of 0.25 ml/kg, and 
the dose of 7,8-DHF was 5 mg/kg. Treatments lasted for 3.5 months. To avoid 
hyperglycaemia-induced symptoms, supportive insulin treatment (100IU/ml, 
Levemir, Novo Nordisk, Denmark) was initiated in hyperglycaemic Wfs1 KO 
rats. Animals with a blood glucose level of 10 mmol/L or more received 2 IU/kg 
insulin, and animals with a blood glucose level of 20 mmol/L or more received 
6 IU/kg insulin twice per day injected subcutaneously (Seppa et al., 2021). 
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performed using a 9.4T Bruker BioSpec 94/20 USR system connected to a 1 H 
circular polarized transceiver coil and running ParaVision 6.0.1® software 
(Bruker BioSpin Group, Bruker Corporations, Germany). Respiration and tem-
perature were monitored using a respiration pillow and a rectal probe (SA Instru-
ments Inc., Stony Brook, USA). Respiration rate was maintained at 35–50 breaths 
per minute. Two orientation pilot scans were performed to establish the position 
of the animal and identify anatomical landmarks relevant for planning the sub-
sequent scan. The final T2-weighted Turbo RARE sequence was performed using 
the following parameters: repetition time (TR) 6803 ms, echo time (TE) 33 ms, 
flip angle 90 degrees, number of averages 5, imaging matrix 320 × 320 × 65, 
spatial resolution 0.16 × 0.16 × 0.5 mm. Volumes were segmented manually by an 
observer blinded to the genotype using ITK-SNAP (V3.6.0) software (Yushkevich 
et al., 2006). The Scalable Brain Atlas (Bakker et al., 2015) was used to determine 
the segmentation start.  
 
4.2.6 Morris water maze (Paper IV) 
On experiment days, the rats were allowed to adapt to the experimental room for 
two hours. The Morris water maze consisted of a 180-cm-diameter plastic pool 
filled with room-temperature water (20–22 °C). The escape platform (diameter, 
14 cm; height, 29 cm) was placed in a fixed position in the centre of one quadrant, 
35 cm from the perimeter, and was hidden 1 cm beneath the water surface. Six 
black and white cues were fixed around the water maze. The water was tinted 
black using tempera paint to allow automatic video recording of albino rats with 
EthoVision software (Noldus Information Technology, Wageningen, Nether-
lands). The acquisition phase lasted four days, and four trials were performed per 
day. For each trial, an animal was placed into the pool at a pseudo-random 
location facing the wall of the pool. Rats were allowed to find the platform during 
a 60-sec session and were guided to the platform if they failed to find it. Rats had 
to remain on the platform for 30 sec before they were rescued and placed in a 
cage filled with paper towels. The next session started after a 60-sec rest period. 
Latency to find the platform and time in the target quadrant were recorded during 
the acquisition phase. The platform was removed on the probe day (fifth day of 
the experiment), rats were released at an unfamiliar location (same for all animals) 
and allowed to search for the platform for 60 sec. Time to find the platform and 
percentage of time in the target quadrant were recorded (Seppa et al., 2021). 
In Paper I and III, for the medulla, segmentation began from the caudal end of 
the inferior colliculus and continued until reaching the most caudal level of the 
cerebellum (bregma −9.48 to −15.48 mm). In all animals, the medulla and EPS 
were measured on 12 consecutive slices (Plaas et al., 2017; Seppa et al., 2019). 
In Paper IV, for the hippocampus, segmentation began from bregma –1.45 mm 
and continued to –5.82 mm until reaching the most caudal end of the thalamus. In 
all animals, the hippocampus was measured on 10 consecutive slices. From the same 
images, lateral ventricles were delineated based on the nearly saturated bright signal 
in T2-weighted images from bregma –3.32 mm to –4.57 mm (Seppa et al., 2021). 
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4.3 Isolation of islets of Langerhans (Paper II) 
Islets of Langerhans were isolated as described previously (Carter et al., 2009). 
0.9 mg/ml collagenase (Sigma-Aldrich, #C7657) solution was injected into the 
common bile duct of euthanized animals; inflated pancreases were collected, and 
tissues were enzymatically dispersed. Most of the exocrine tissue was removed 
by gradient separation in Histopaque solution (Sigma-Aldrich). Islets of Langer-
hans were collected by hand from the remaining exocrine tissue under a stereo 
microscope (Toots et al., 2018). 
 
 
4.4 RNA isolation, cDNA synthesis and  
gene expression analyses (Paper I, II, IV) 
RNA was isolated using Direct-zol RNA MiniPrep (Zymo Research, R2052) 
according to the manufacturer’s protocol. RNA concentration and quality were 
assessed with NanoDrop 2000c (Thermo Fisher Scientific). 500 ng RNA was used 
for cDNA synthesis. Random Hexamer Primers 120 µl 0.2 µg/ul (Thermo Fisher 
Scientific, Cat# SO14, dNTP Mix (10 mM) (Invitrogen, Cat# 18427013) and 
SuperScript III Reverse Transcriptase (200 units/µl) (Thermo Fisher Scientific, 
Cat# 18080044) were used to synthesize first-strand cDNA. Taqman Gene 
Expression Mastermix (Thermo Fisher Scientific, Cat# 4369016) and TaqMan 
Gene Expression Assays in reaction volume 10 ul were used for qRT-PCR. The 
following assays were used, as shown on table 2. Hprt1 was used as an internal 
control, and the 2−∆Ct method was used for relative quantification. Xbp1 (X-box 
binding protein 1) splicing was analysed using rat Xbp1-specific PCR, as has been 
described previously (Yusta et al., 2006). Integrated density levels were measured 
using ImageJ software (Plaas et al., 2017; Seppa et al., 2021; Toots et al., 2018). 
 
Table 2. TaqMan Gene Expression Assays 
Gene Assay ID Paper 
Chop Rn00492098_g1 I, IV 
Grp78 Rn00565250_m1 I, II, IV 
FoxP2 Rn01456150_m1 I, 
Wfs1 Rn00582735_m1 I, 
Ip10 Rn01413889_g1 II, IV 
Ki67 Rn01451446_m1 IV 
Tlr2 Rn02133647_s1 IV 
Tlr4 Rn00569848_m1 IV 




4.5 Insulin, C-peptide, and glucagon measurements  
(Paper II) 
For serum separation, blood was allowed to clot at room temperature for 30 min 
and then was centrifuged for 15 min at 2000 × g at 4 °C. Blood serum samples 
were stored in −80 °C until further analysis. Serum insulin, c-peptide and gluca-
gon levels were measured using ELISA kits: rat insulin ELISA kit (CrystalChem 
cat# 90060), rat C-peptide ELISA (CrystalChem cat# 90055), and rat glucagon 
ELISA (CrystalChem cat# 81519), according to the manufacturer’s instructions 
(Toots et al., 2018). 
 
 
4.6 Immunohistochemistry  
4.6.1 Tissue preparation (Paper I, II, III) 
Rats were anaesthetized with an intraperitoneal injection of ketamine (100 mg/kg) 
and dexmedetomidine (20 mg/kg) in a volume of 10 ml/kg. Thereafter, rats were 
perfused transcardially with 300 ml PBS and then with 300 ml 4% paraformal-
dehyde (PFA, Sigma-Aldrich) in a 0.1 M phosphate buffer (PB, pH 7.4). Tissues 
(pancreas or/and brain) were dissected and further fixed in the same fixative 
overnight at 4 °C. Tissues were placed in a 30% sucrose (AppliChem)/0.1 M PBS 
until they sank and then were frozen at –80 °C until further use.  
 
 
4.6.2 Immunohistochemistry of the brainstem (Paper I) 
40 µm thick sections of the brainstem were cut using a cryomicrotome (Microm 
HM-560) and collected on Superfrost Polysine Slides (Thermo Scientific). After 
washing with phosphate buffered saline (PBS) for 10 min, sections were 
permeabilized with 0.2% Triton X-100 (Naxo, Tartu, Estonia)/PBS solution for 
40 min. Sections were further incubated in a blocking solution containing 5% 
donkey serum/1% bovine serum albumin (BSA, Sigma-Aldrich)/PBS for 2 h at 
room temperature. Primary and secondary antibodies were diluted in 0.1% 
Tween-20/1% BSA/PBS. Sections were incubated with primary antibodies for 
12 h at 4 °C and were then washed with PBS for 1 h. Sections were incubated 
with the appropriate secondary antibody at room temperature for 2 h. After 
subsequent washes with PBS (1 h), cell nuclei were counterstained with DAPI 
(4′,6-diamidino-2-phenylindole, Sigma-Aldrich) at a 1:2000 dilution in 0.1% 
Tween-20/PBS for 15 min and further washed with PBS. Sections were mounted 
in Vectashield mounting medium (Vector Laboratories Inc.) and covered with a 
0.17-mm coverslip (Deltalab). Images were taken with an Olympus FV-1000 
(Olympus) confocal microscope or Olympus BX51 Fluorescence Microscope 
and annotated with Adobe Photoshop CC (Adobe Systems Incorporated). 
Primary antibodies and their dilutions were as follows: goat anti-FOXP2 
(1:400, Everest Biotech, Cat# EB05226, Lot# 160409) and rabbit anti-WFS1 
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(1:400), as previously described (Luuk et al., 2008). Secondary antibodies and 
their dilutions were as follows: FITC AffiniPure donkey anti-rabbit (1:1000, 
Jackson ImmunoResearch Lab., 711–095–152, RRID:AB_2315776) and Rhoda-
mine Red-X-AffiniPure rabbit anti-goat (1:1000, Jackson ImmunoResearch Labs 
Cat# 305-297-003, RRID:AB_2339496) (Plaas et al., 2017). 
 
 
4.6.3 Determination of Langerhans islet mass (Paper I, II) 
Langerhans islet mass was estimated as has been previously described (Iglesias 
et al., 2012). Pancreases were weighed, and 40-μm-thick serial sections were cut 
at intervals of 400 μm. 20–30 slices per pancreas were obtained and analysed. 
Sections were washed with PBS for 3 × 5 min, permeabilized with 0.2% Triton 
X-100 (Naxo, Estonia)/PBS solution for 30 min, incubated in 0.5% H2O2/PBS for 
1 h, and blocked in 5% donkey serum/1% bovine serum albumin (BSA, Sigma-
Aldrich)/PBS for 1 h. Primary and secondary antibodies were diluted in 0.1% 
Tween-20/1% BSA/PBS. Sections were incubated with mouse anti-insulin 
antibody (1:800, Cell Signaling Technology Cat# 8138 S RRID: AB_10949314) 
for 1 h and washed with PBS for 3 × 10 min, followed by incubation with donkey 
anti-mouse peroxidase conjugated antibody (1:2000, Rockland Cat# 610-703-
002 RRID: AB_219700) for 30 min and washed with PBS 3 × 5 min. Sections 
were incubated in 0.025% diaminobenzidine (Sigma Aldrich)/0.005% 
H2O2/0.05% CoCl2 (Sigma Aldrich)/PBS for 15 min and washed with water. 
Dried sections were mounted using PeRtEx (HistoLab) and covered with a 
0.17 mm coverslip (Deltalab). Images were taken using a Leica SCN 400 slide 
scanner at 20x magnification. The images obtained were analysed using ImageJ 
software. Langerhans islet mass was calculated using the following equation: 
Langerhans islet mass (mg) = pancreas weight (g) × relative Langerhans islet 
surface (total islet area mm2 /total pancreas area mm2) × 1000 (Plaas et al., 2017; 
Toots et al., 2018). 
 
 
4.6.4 Immunohistochemistry of inferior olive (Paper III) 
Brainstems were serially sectioned, 50 μm coronally from caudal to rostral, 
Bregma level −13.30 to −11.80 mm (Paxinos and Watson, 2014) on a Microm 
HM355 cryostat (Microm International GmbH, Walldorf, Germany). Systematic 
series of sections were saved in cryoprotectant solution. Sections were washed 
(3 × 5 min) in Tris buffered saline (TBS) containing 0.3% Triton X-100 (TBST 
buffer), and then endogenous peroxidases were deactivated by incubating in 
peroxidase block (hydrogen peroxide) for 10 min with gentle agitation. Next, 
sections were rinsed with TBS and incubated with target retrieval solution (Dako, 
Glostrup, Denmark) for 30 minutes at 80 °C and washed again with TBST 
(3 × 5 min). Sections were blocked with blocking solution containing 10% goat 
serum/1% bovine serum albumin (BSA, Sigma-Aldrich)/TBST or 1% bovine 
serum albumin (BSA, Sigma-Aldrich)/TBST for 1 h at room temperature. Primary 
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and secondary antibodies were diluted in 1% BSA/TBST. Sections were incu-
bated with primary antibodies overnight at 4 °C with gentle agitation and were 
then washed with TBST (3 × 15 min). Sections were incubated with the appro-
priate secondary antibody at room temperature for 2 h. After subsequent washes 
with TBS (3 × 15 min), sections were placed in solution for DAB reaction 
(Sigma–Aldrich) (10 min). Sections were washed with TBS (3 × 10 min), mounted 
on SuperFrost glass slides (MenzelGlaser) using 0.5% Gelatine (Sigma–
Aldrich) + 0.05% Chromalum (BDH Chemicals Ltd) dissolved in distilled water, 
dried at room temperature for 20 min, rehydrated in distilled water for 15 min, 
and dehydrated in a graded series of ethanol solutions (2 min in 96%, 5 min in 
99%). Finally, sections were cleared for 3 × 5 min in xylene, and cover slips 
(No. 0, Hounisen) were mounted using Eukitt Quick-hardening mounting 
medium (Sigma–Aldrich) (Seppa et al., 2019). 
Primary antibodies and their dilutions were as follows: rabbit anti-GRP78 
antibody (Abcam ab31390; 1:2000), goat anti-IBA1 antibody (Abcam ab107159; 
1:1000), and rabbit anti-GFAP antibody (Synaptic Systems ab887720; 1:1000). 
Secondary antibodies and their dilutions were as follows: goat anti-rabbit 
(DAKO, REF P0448; 1:400) and rabbit anti-goat (DAKO, REF PO449; 1:400) 
(Seppa et al., 2019). 
For illustrative panels (Figure 13–15), a Leica DM750 light microscope, a 
Leica HI PLAN 40x lens (NA = 0.17) and a Leica ICC50 HD, controlled by Leica 
Application Suite v.4.6.0 software, were used (Leica Microsystems, Switzerland) 
(Seppa et al., 2019). 
 
 
4.6.5 Stereological estimate of inferior olive  
neuron number (Paper III) 
Sections were stained in 0.25% thionin (CAS 78338-22-4, Sigma–Aldrich, St. 
Louis, Missouri, USA) for 60 sec, rinsed in distilled water for 5 sec, and dehyd-
rated in a graded series of ethanol solutions (1 min in 70%, 2 min in 96%, 5 min 
in 99%). After clearing in xylene for 3 × 5 min, cover slips (No. 0, Hounisen, 
Skander-borg, DK) were mounted using Eukitt Quick-hardening mounting 
medium (CAS 25608-33-7, Sigma–Aldrich, Steinheim, DE). Sections were 
analysed using an Olympus BX51 light microscope (Olympus) equipped with a 
Prior motorized stage, a Heidenhain microcator, an Olympus UPlanApo 4× lens 
(NA = 0.16), an Olympus UPlanSApo 60× oil lens (NA = 1.35) and an Olympus 
DP70 digital camera controlled by newCAST (Visiopharm, Hoersholm, Den-
mark) software. There are three major subnuclei in the inferior olive: the medial 
nucleus, dorsal nucleus and principal nucleus. Delineation of the region of interest 
(ROI) was performed using a 4× objective, and the analyses were performed with 
a 60× oil objective, with total magnification of 2791.36 (Figure 17). The total 
number of neurons, N(neu), in the inferior olive was estimated using the optical 
fractionator (Gundersen, 1977, 1986; Dorph-Petersen et al., 2001): 
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𝑁 𝑛𝑒𝑢 = 1𝑠𝑠𝑓 ∙ 1𝑎𝑠𝑓 ∙ 1ℎ𝑠𝑓 ∙  𝑄 𝑛𝑒𝑢   
 
where ssf, asf and hsf are referred to as the section sampling fraction (1/4); the 
area sampling fraction (counting frame area/(dx×dy)), in which (dx×dy) indicates 
step length in the x- and y-direction; and height sampling fraction (h/tQ–, 
respectively. The height is denoted h and Q–weighted section thickness is denoted 
tQ–, and ∑Q− (neu) is the total number of neurons counted per rat in all examined 
sections. The step lengths in the x- and y-direction were 123 µm, and the area of 
the unbiased counting frame was 2125 µm2. The guard height was 5 µm, and the 
disector height, h, was 10 µm, determined following a z-axis analysis. Cell soma 
volume estimates of individual neurons were estimated using the spatial rotator 
(Rasmusson et al., 2013). A systematic set of sections was used for the determi-
nation of cell density using the optical disector for GRP78, IBA1 and GFAP 




where p denotes the number of test points per counting frame; P denotes total 
number of test points hitting the ROI, and ∑Q− (cell) marks the total number of 
cells counted per rat in all examined sections. The counting frame area was 
2125 µm2, and the height, h, was 10 µm (Seppa et al., 2019). 
 
 
4.7 Data analysis (Paper I, II, III, IV) 
GraphPad Prism version 5 software (GraphPad Software Inc., San Diego, CA, 
USA), STATISTICA 8 package (StatSoft Inc, Tulsa, OK, USA) or GBStat V 8 
(Dynamic Microsystems Inc., Silverspring, MD, USA) were used for statistical 
analysis, and p < 0.05 was considered statistically significant. The data are 
presented as the mean ± SEM and were compared using factorial ANOVA 
followed by Fisher’s LSD tests, one-way ANOVA followed by Tukey’s HSD 
tests or repeated measures ANOVA followed by Bonferroni post hoc test (Plaas 
et al., 2017; Seppa et al., 2019, 2021; Toots et al., 2018). 
  
𝑁  cell = ∑ 𝑄 𝑐𝑒𝑙𝑙ℎ ∙ 𝑎/𝑝 ∙  ∑ 𝑃 = ∑ 𝑄 𝑐𝑒𝑙𝑙ℎ ∙ 𝑐𝑜𝑢𝑛𝑡𝑖𝑛𝑔 𝑓𝑟𝑎𝑚𝑒 𝑎𝑟𝑒𝑎𝑝 ∙  ∑ 𝑃 
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5 RESULTS AND DISCUSSION 
5.1 Paper I  
5.1.1 Development of glucose intolerance 
First symptom required for Wolfram syndrome diagnosis is diabetes mellitus, 
which manifests at the age of 6 years (Rigoli et al., 2018). Degeneration of WFS1-
expressing pancreatic beta cells is the cause for inadequate secretion of insulin 
and developing diabetes mellitus (Cano et al., 2007). Therefore, our aim was to 
investigate the development of diabetes mellitus in the Wfs1 KO rat on the 
molecular and functional level. 
ER stress response in the lysates of isolated islets of Langerhans was evaluated 
by performing real-time quantitative PCR (qRT-PCR) analysis of the ER stress 
markers Grp78 and spliced Xbp1. At the age of 3 months, Xbp1 expression was 
increased in Wfs1 KO animals compared to WT littermates (Figure 3c). At the 
age of 7 months, the difference had increased (Figure 3d). No significant dif-
ferences were detected between genotypes in Grp78 expression (Figure 3a, b). 
This was probably due to different expression dynamics of Grp78 and spliced 
Xbp1 in pancreatic islets (Plaas et al., 2017). 
Next, the functionality of Langerhans islets was assessed through an intraperi-
toneal glucose tolerance test that was performed at the age of 2, 3 and 6 months. 
At the age of 2 and 3 months, Wfs1 KO rats showed a progressive decrease in 
glucose tolerance (Figure 4a, b), and at the age of 6 months, Wfs1 KO rats had 
developed glucose intolerance (Figure 4c), which was confirmed by an area-
under-the-curve analysis (Figure 4d) (Plaas et al., 2017).  
As cellular stress was increased in isolated Langerhans islets, and the 
functionality of the Langerhans islets decreases over time, our next purpose was 
to assess Langerhans islet mass in time. Therefore, quantitative histological 
analyses were performed, and similarly to glucose tolerance data, at the age of 
3 months, Langerhans islet mass was unchanged between genotypes (Figure 5a). 
Langerhans islet mass started to decline from the age of 7 months (Figure 5b), 
and at the age of 14 months, the rate of decline increased (Figure 5c) (Plaas et al., 
2017).  
Reduced glucose tolerance was in accordance with progressive decline of 
Langerhans islets, and this confirms that developing glucose intolerance is due to 
the degeneration of pancreatic Langerhans islets. Therefore, our results indicate 
a similar course of the development of diabetes mellitus in Wolfram syndrome 





Figure 3. Wfs1 KO (KO) rats have elevated ER stress in Langerhans islets. qRT-PCR 
analysis of the ER stress markers (a, b) Grp78 and (c, d) spliced Xbp1 in lysates of isolated 
Langerhans islets at the age of 3 and 7 months. The data were compared using t-tests; 
*p < 0.05; **p < 0.01. The data are presented as the mean ± SEM, n = 5 to 8 (Plaas et 
al.,2017). 
 











































































































Figure 4. At the age of 6 months, Wfs1 KO (KO) rats have developed glucose 
intolerance. For intraperitoneal glucose tolerance tests (IPGTTs), blood glucose levels 
were measured after administration of glucose (2 g/kg i.p.), and the area under the curve 
was calculated. Glucose tolerance at the age of (a) 2 months, (b) 3 months and 
(c) 6 months. (d) Area-under-the-curve analyses from IPGTT results at different ages. 
The data were compared using two-way ANOVAs followed by Tukey’s HSD tests; 
**p < 0.01. The data are presented as the mean ± SEM, n = 6–8 (Plaas et al., 2017). 
 
 
Figure 5. Wfs1 KO (KO) animals’ Langerhans islet mass decreases in time. Quantitative 
histological analyses were performed to measure Langerhans islet mass. Langerhans islet 
mass at the age of (a) 3 months, (b) 7 months and (c) 14 months. The data were compared 
using two-way ANOVAs followed by Tukey’s HSD tests; *p < 0.05, **p < 0.01. The data 
are presented as the mean ± SEM, n = 6–8 (Plaas et al., 2017).  
















































































































































5.1.2 Development of neurodegeneration 
Quantitative neuroimaging studies have shown a loss of brainstem volume in 
Wolfram syndrome patients (Hershey et al., 2012; Lugar et al., 2016), and 
degeneration of the inferior olive is a recognized feature of Wolfram syndrome 
(Barrett and Bundey, 1997; Genís et al., 1997; Hilson et al., 2009; Khardori et al., 
1983). Thus, we hypothesized that brainstem atrophy and inferior olive neuro-
degeneration are also present in Wfs1 KO rats. To test this hypothesis, we per-
formed an immunohistochemistry analysis of the brainstem to find out if WFS1 
is expressed in the olive nucleus. As FOXP2 (forkhead box P2) is visibly localized 
in all olive nucleus neurons throughout development, FOXP2 can be considered 
as a molecular marker of olive nucleus neurons (Fujita and Sugihara, 2012). There-
fore, double immunofluorescence procedure was carried out and indeed, WFS1 
is expressed in the brainstem, and WFS1 was localized mainly in the inferior olive 
(IO) (Figure 6a), exclusively in FOXP2-positive neurons (Figure 6c). FOXP2 
neurons are excitatory neurons that terminate as climbing fibres in the cerebellum 
(Fujita and Sugihara, 2012). Climbing fibres play a central role in the execution 
and adaptation of motor behaviours (McKay et al., 2007) and thus, WFS1 might 
have a role in modulating motor behaviours.  
Next, using gene expression analyses, ER stress levels were measured at the 
ventral brainstem at the level of the inferior olive. Grp78 mRNA expression was 
unchanged at the age of 3 months, and at the age of 7 months, Grp78 mRNA 
levels were elevated in Wfs1 KO animals compared to WT littermates (Figure 7b), 
which indicates ER stress at the level of the inferior olive. No significant 
differences were detected in Chop mRNA expression between Wfs1 KO and WT 
littermates (Figure 7c, d). This indicates that ATF6 pro-survival pathway of UPR 
response was activated and not the CHOP apoptosis pathway (Figure 2). 
Moreover, it has been shown that forced activation of the ATF6 UPR branch 
improved functional outcome and reduced infarct volume after stroke in condi-
tional ATF6 knock-in mouse. Therefore, boosting UPR pro-survival pathways 
may be a promising therapeutic strategy for stroke and other ER associated 
diseases (Yu et al., 2017). 
Quantitative in vivo MRI analysis revealed that, at the age of 15 months, 
brainstem volume per slice at the level of the inferior olive was reduced in 
Wfs1 KO rats compared to WT littermates (Figure 8d). Additionally, at the age 
of 15 months, the volume of the extraparenchymal space around the medulla was 
increased in Wfs1 KO rats compared to WT littermates, as seen in the total 
volume (Figure 8b) and in the volume per slice (Figure 8d).  
Indeed, the reduced volume of medulla in Wfs1 KO rats shows similarities to 
the reduced volumes of medulla observed in Wolfram syndrome patients 
(Hershey et al., 2012). Additionally, the Wfs1 KO rat develops diabetes mellitus 
(Figure 4), as well as patients with Wolfram syndrome (Rohayem et al., 2011). 
Hence, the Wfs1 KO rat has the core symptoms of Wolfram syndrome. Therefore, 
the Wfs1 KO rat is a valuable Wolfram syndrome animal model and can be used 
to develop treatment strategies. 
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Figure 6. WFS1 protein is expressed in the inferior olive in the brainstem. (a–c) 
Immunohistochemical analysis revealed that WFS1 is localized in the inferior olive. (b) 
Higher magnification of the inferior olive from the red rectangle shows the cytoplasmic 
localization of WFS1 and that (c) WFS1 and FOXP2 were localized in the same set of 
cells in the IO (Plaas et al., 2017).  
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 Figure 7. At the age of 7 months, Wfs1 KO (KO) rats have elevated ER stress in the 
brainstem at the level of the inferior olive. qRT-PCR analysis of the ER stress marker 
Grp78 mRNA at the age of (a) 3 months and (b) 7 months and Chop mRNA at the age of 
(c) 3 and (d) 7 months. The data were compared using two-way ANOVAs followed by 
Tukey’s HSD tests; **p < 0.01. The data are presented as the mean ± SEM, n = 8 to 10 
(Plaas et al., 2017). 







































































































Figure 8. At the age of 15 months, Wfs1 KO (KO) rats have developed neurodegene-
ration in the brainstem at the level of the inferior olive. Results of quantitative MRI 
analysis of (a) the volume of medulla and (b) extraparechymal space (EPS). Volume per 
slice measurement data from (c) 8-month-old animals and from (d) 15-month-old animals. 
Representative MR images (e–h). At the age of 15 months, the ventral surface of the 
brainstem of Wfs1 KO rats appears to be more concave (arrowhead). The data were 
compared using two-way ANOVAs followed by Fisher’s LSD tests; **p < 0.01 between 
genotypes. The data are presented as the mean ± SEM, n = 6–7 (Plaas et al., 2017).
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5.1.3 Conclusion from Paper I 
First, we showed that Wolfram syndrome rats develop ER stress in pancreatic 
Langerhans islets, degeneration of Langerhans islets and resultant glucose 
intolerance. Next, we described how WFS1 is expressed in the brainstem and that 
WFS1 was localized mainly in the inferior olive. In addition, in Wolfram syndrome 
rats’ inferior olive there is elevated ER stress. Furthermore, at the level of the 
inferior olive, brainstem volume per slice was reduced, and the volume of the 
extraparenchymal space was increased. Together, these results demonstrate that 
ER stress occurs prior to cellular loss in the pancreas and decreases in brainstem 
volume in Wfs1 KO rats. Based on the information above, we conclude that the 
Wolfram syndrome rat develops glucose intolerance and neurodegeneration, and 
thus, the Wolfram syndrome rat model is suitable for investigating treatment 
options for Wolfram syndrome.  
 
 
5.2 Paper II  
The GLP-1 receptor agonist liraglutide was approved in Europe in 2009 for the 
treatment of diabetes mellitus and obesity, and since the approval, its neuro-
protective effect has also been demonstrated in animal models of stroke (Sato et 
al., 2013), Alzheimer’s disease (Hansen et al., 2016) and Parkinson’s disease (Liu 
et al., 2015). As diabetes mellitus and neurodegeneration are also the core symp-
toms of Wolfram syndrome, our goal was to test the potential therapeutic effect 
of the GLP-1 receptor agonist liraglutide. We started with the liraglutide treat-
ment before the development of diabetes to determine if liraglutide treatment can 
prevent the development of diabetes mellitus in the Wolfram syndrome rat model. 
At the beginning of the experiment, animals were 2 months old, and they were 
treated for 5 months with liraglutide (n=55, 12–15 per group) (Toots et al., 2018). 
 
 
5.2.1 Liraglutide treatment protects against development  
of glucose intolerance 
First, in vivo IPGTT was performed when the animals were 2 months old, and the 
results showed that there were no differences between the experimental groups at 
the beginning of the experiment (Figure 9a). Next, IPGTT’s were performed after 
2, 3.5, and 5 months of liraglutide treatment (Figure 9b–d). Figure 9 shows that 
saline-treated Wfs1 KO (KO Sal) animals develop glucose intolerance over time, 
while liraglutide-treated animals’ glucose tolerance stayed at the same level as 
saline-treated wild-type (WT Sal) animals. This indicates that liraglutide treat-
ment had a therapeutic effect and protected Wolfram syndrome rats from 
developing glucose intolerance (Toots et al., 2018). 
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Figure 9. Liraglutide treatment protected Wfs1 KO (KO) rats from developing glucose 
intolerance. Intraperitoneal glucose tolerance tests (IPGTTs) were performed after 
administration of glucose (2 g/kg i.p.), and the area under the curve was calculated (a) at 
the beginning of the experiment, (b) after 2 months, (c) 3.5 months and (d) 5 months of 
liraglutide treatment. The data were compared using one-way ANOVA followed by 
Tukey’s HSD tests; ***p < 0.001. The data are presented as the mean ± SEM, n=12–15 
(Toots et al., 2018). 
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5.2.2 Liraglutide treatment protects Langerhans islets from ER stress  
After 5 months of treatment, rats were euthanized, and gene expression analyses 
were performed to evaluate the effects of liraglutide treatment at the molecular 
level. First, ER stress marker Grp78 mRNA levels were measured using qRT-
PCR. In saline-treated Wfs1 KO animals, Grp78 mRNA levels were elevated 
compared to WT Sal animals, which indicates ER stress in Wfs1 KO animals. 
Liraglutide treatment had a protective effect on Wfs1 KO rats’ pancreatic islets, 
as liraglutide-treated Wfs1 KO rats’ Grp78 expression levels were indistinguish-
able from WT Sal animals (Figure 10a). Similarly to Grp78 expression level, 
there was also a tendency to have elevated ER stress marker Xbp1s levels in 
Wfs1 KO animals, although the difference was not significant (Figure 10b). IP10 
is an inflammatory chemokine that mediates immune responses through the acti-
vation and recruitment of leukocytes. IP10 is crucial for perpetuation of inflam-
mation which leads to tissue damage (Vazirinejad et al., 2014). Here, inflam-
mation marker Ip10 mRNA levels were measured, and there was a tendency to 
have elevated inflammation in KO Sal animals, although the difference was not 
significant (Figure 10c). However, liraglutide treatment lowered the inflammation 
in Wfs1 KO animals compared to saline-treated Wfs1 KO animals, indicating an 
anti-inflammatory effect (Figure 10c). Cellular stress and inflammation lead to 
the development of diabetes mellitus (Oguntibeju, 2019) and by suppressing the 
inflammation and cellular stress, as we showed here and which has also been 
shown previously (Langlois et al., 2016), it could be possible to prevent the 
development of diabetes mellitus (Toots et al., 2018). 
 
Figure 10. 5-month liraglutide treatment reduces cellular stress and inflammation in 
Wfs1 KO (KO) rats’ pancreases. qRT-PCR analysis of isolated Langerhans islets, which 
were extracted from rats after 5 months of liraglutide treatment. ER stress markers 
(a) Grp78 and (b) Xbp1s, inflammation marker (c) Ip10. The data were compared using 
factorial ANOVA followed by Tukey’s HSD tests; *p < 0.05. The data are presented as 


















































































































5.2.  Liraglutide treatment maintains Langerhans islet mass 
We can suggest that in Wolfram syndrome rats, ER stress leads to inflammation 
and possibly to a decrease in insulin secretion, as seen in developed glucose 
intolerance in IPGTT. It is known that the human Langerhans islet consists 
mostly of insulin-secreting beta cells, which make up 60 percent of the total mass, 
along with 30% glucagon-producing α-cells and 10% somatostatin-producing  
δ-cells, pancreatic polypeptide-producing γ- or PP cells, and ghrelin-producing 
ε-cells (Da Silva Xavier, 2018). WFS1 is mainly expressed in the islets’ β-cells, 
and some expression is also found in δ-cells, but not in α-cells (Ueda et al., 2005). 
Hence, our next question was if glucose intolerance resulted from loss of insulin-
secreting beta cell mass. To answer this question, our aim was to measure the 
Langerhans islet mass. Therefore, immunohistochemistry was performed. In 
agreement with previous results (Figure 5), Langerhans islet mass had declined 
in Wfs1 KO rats compared to WT saline-treated animals (Figure 11b), and 
liraglutide treatment was able to maintain Langerhans islets mass in Wfs1 KO 
animals. Surprisingly, Langerhans islet mass had also decreased in liraglutide-
treated WT animals. Liraglutide is approved for chronic weight management in 
individuals with overweight or obesity (Garvey et al., 2020). Here we saw a 
strong body-weight-decreasing effect of liraglutide in both genotypes as well 
(Figure 11a). To take this into account, we divided Langerhans islet mass by body 
weight (Figure 11c), and consequently, the significance disappeared between WT 
animals’ treatment groups (Figure 11c). Indeed, glucose intolerance might be 
caused by a decrease of the Langerhans islet mass, which in turn, is due to cellular 
stress and inflammation (Toots et al., 2018).  
Figure 11. 5-month liraglutide treatment was able to maintain the mass of Langerhans 
islets in Wfs1 KO (KO) animals. To calculate the mass of Langerhans islets from the 
pancreas, immunohistochemistry was performed, and Langerhans islets were measured 
from anti-insulin antibody-stained pancreatic slices. (a) Body weight changes during 
liraglutide chronic treatment, (b) Langerhans islet mass, (c) Langerhans islet mass divided 
by body weight. The data were compared using one-way ANOVA followed by Tukey’s 
HSD tests; *p < 0.05, **p < 0.01. The data are presented as the mean ± SEM, n = 4–6 
(Toots et al., 2018).  
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 5.2.4 Liraglutide treatment maintains Langerhans  
islet cells’ cellular function 
Liraglutide treatment had no statistically significant treatment effect on Langer-
hans islets’ mass, although liraglutide treatment protected against the develop-
ment of glucose intolerance in vivo. This may indicate that when the pancreatic 
beta cells are protected from cellular stress and inflammation, the cells retain their 
functionality and are able to secrete sufficient insulin. This hypothesis is con-
firmed by hormone measurements, which indicate that in liraglutide-treated 
Wfs1 KO animals, c-peptide and glucagon secretion was similar to WT Sal animals 
(Figure 12b, c). In addition, insulin secretion was slightly better in liraglutide-
treated animals compared to Wfs1 KO saline-treated animals (Figure 12a). 
Exenatide’s acute antihyperglycaemic effect has been shown in a Wfs1-defi-
cient mouse model (Sedman et al., 2016). Additionally, after publication of the 
current study, Kondo et al. showed in Wfs1-deficient mouse model that 4-week 
exenatide treatment resulted in restored glucose tolerance in IPGTT without 
affecting beta cell mass, similarly to our results (Kondo et al., 2018). They also 
described liraglutide’s effect in a female Wolfram syndrome patient: 16 weeks of 
treatment with liraglutide modulated beta cell function and improved glycaemic 
control (Kondo et al., 2018). Furthermore, a recent study investigated a 15-year-
old female patient with autosomal dominant WFS1-related disorder who had been 
on insulin-replacement therapy. Weekly subcutaneous administration of a GLP-
1 agonist, dulaglutide, led to improved glycaemic control, and no additional 
insulin was needed thereafter (Scully and Wolfsdorf, 2020).  
Our data and previous research indicate that liraglutide has a strong anti-
inflammatory effect that maintains or restores cellular functionality. However, 
further research is required to clarify this phenomenon. 
Figure 12. 5-month liraglutide treatment maintains Langerhans islet cells’ cellular 
function in Wfs1 KO (KO) rats. Blood serum was collected before and 30 minutes after 
glucose administration during an intraperitoneal glucose tolerance test (IPGTT) and 
thereafter (a) insulin, (b) c-peptide and (c) glucagon levels were measured using ELISA 
kits. The data were compared using repeated measures ANOVA followed by Tukey’s 
HSD tests; *p < 0.05, **p < 0.01, ***p < 0.001. The data are presented as the 











































































































5.2.5 Conclusion from Paper II 
5-month preventive liraglutide treatment protected Langerhans islets from ER 
stress, maintained Langerhans islets’ cellular function and mass and thereby 
protected Wfs1 KO rats against development of glucose intolerance. Indeed, 
liraglutide had a protective effect against developing diabetes mellitus; however, 
it is still unknown whether liraglutide has a preventive or only delaying effect on 
diabetes in Wolfram syndrome rats. Additionally, liraglutide’s effect on other 
Wolfram syndrome symptoms is still unknown (Toots et al., 2018). 
 
 
 5.3 Paper III  
Wolfram syndrome rats develop brainstem atrophy at the level of the inferior 
olive (Figure 8d). Therefore, our next aim was to investigate whether liraglutide 
has a similar protective effect on the olive nucleus as it had on pancreatic beta 
cells. To mimic the relatively late diagnosis of Wolfram syndrome patients, we 
took 9-month-old animals who had already developed diabetes and treated them 
for 6 months with liraglutide (n = 32, 6–8 per group). Our goal was to determine 




5.3.1 Liraglutide treatment protects against ER stress  
in the inferior olive 
First, stereological estimation of GRP78-positive cells (Figure 13a–d) was per-
formed using the optical disector to estimate neuron densities. Since the volume 
of the different nuclei in the inferior olive was unchanged between groups (Figure 
17), differences in neuron density can be regarded as changes in their total 
number. There were no differences in the medial nucleus (Figure 13e) nor in the 
dorsal nucleus (Figure 13f). However, there was an increased number of GRP78-
positive cells in Wfs1 KO animals’ principal nucleus (Figure 13g) and in all 
inferior olive nuclei together (Figure 13h). Liraglutide treatment decreased ER 
stress in Wfs1 KO animals’ inferior olive (Figure 13g, h). This finding agrees 
with the previous results. Elevated ER stress levels are detected in Wfs1 KO rats’ 
pancreases (Figure 3c, d) and in the ventral brainstem (Figure 7b). Additionally, 
liraglutide treatment reduced Grp78 levels in Langerhans islets (Figure 10a). 
Thus, liraglutide treatment appears to have similar ER stress-lowering effects on 
both beta cells and on neurons in a rat model of Wolfram syndrome (Seppa et al., 
2019). A similar ER stress response in beta cells and neurons suggests that the 
Wfs1 KO rat is a good animal model to study both diabetes and neuro-
degeneration (Seppa et al., 2019). 
44 
 Figure 13. Liraglutide treatment protects Wfs1 KO (KO) rats against ER stress in the 
inferior olive. Representative histological images of GRP78-positive cells after 6 months 
of liraglutide/saline treatment in every treatment group and genotype (a) WT Sal, (b) WT 
Lira, (c) KO Sal, (d) KO Lira. Stereological quantification of cell density of GRP78-
positive neurons was performed in the (a) medial nucleus; (b) dorsal nucleus; (c) principal 
nucleus; and (d) in all inferior olive nuclei together. The data were compared using 
factorial ANOVA followed by Fisher’s LSD tests; *p < 0.05, **p < 0.01. The data are 





























































































































5.3.2 Liraglutide treatment protects against neuroinflammation  
in the inferior olive 
The neuroinflammation response, as measured by activated microglia (Hickman 
et al., 2018) and astroglia (Li et al., 2019) is a common feature of neuro-
degeneration. Hence, our next aim was to evaluate the neuroinflammatory 
response in the inferior olive. Therefore, the optical disector was used to estimate 
GFAP-positive astroglia cell densities in every treatment group (Figure 14 a–d), 
as GFAP is considered a marker protein for astrogliosis (Eng et al., 2000). The 
density of GFAP-positive astrocytes was increased in saline-treated Wfs1 KO 
animals compared to WT littermate animals, and liraglutide treatment protected 
Wfs1 KO animals from neuroinflammation (Figure 14e) (Seppa et al., 2019). 
Mild gliosis has also been reported in connection with Wolfram syndrome. A 37-
year-old female Wolfram syndrome patient’s post-mortem case study revealed 
mild gliosis in the spinal cord, hypothalamus, superior colliculi, inferior colliculi, 
vagus dorsal nuclei and ambiguus nuclei, in the anterior and dorsomedial nuclei 
of the thalamus, preoptic and paraventricular nuclei and in the substantia nigra 
(Genís et al., 1997). Also, a 38-year-old female Wolfram syndrome patient’s case 
study showed widespread mild fibrillary gliosis in the superior and inferior 
colliculi, anterior and dorsomedial nucleus of the thalamus and, in addition, 
gliosis in the cochlear nuclei, mammillary bodies, mesencephalic, pontine and 
medullary tegmentum and the olfactory tracts and bulbs (Shannon et al., 1999). 
However, gliosis has not been described in the olive nucleus of Wolfram 
syndrome patients. 
Ionized calcium-binding adapter molecule 1 (IBA1) is a microglial marker 
whose expression increases with microglial activation (Hopperton et al., 2018). 
Hence, to measure microglial activation, IBA1-poitive microglia cell densities in 
every treatment group were measured (Figure 15 a-d). IBA1-positive microglia 
cell density was increased in saline-treated Wfs1 KO animals compared to WT 
littermate animals, which indicates neuroinflammation in the inferior olive 
(Figure 15e). Treatment with liraglutide prevented such an increase in Wfs1 KO 




Figure 14. Liraglutide treatment protects against neuroinflammation in the inferior olive 
of Wfs1 KO (KO) rats. Representative histological images of GFAP positive astroglia 
cells after 6 months of liraglutide/saline treatment in every treatment group and genotype 
(a) WT Sal, (b) WT Lira, (c) KO Sal, (d) KO Lira. (e) Stereological quantification of 
GFAP-positive cells in the inferior olive after 6 months of liraglutide treatment. The data 
were compared using factorial ANOVA followed by Fisher’s LSD tests, ***p < 0.001. 
The data are presented as the mean ± SEM, n = 6–8 per group. Scale bar 200 µm (Seppa 



































Figure 15. Liraglutide treatment protects against neuroinflammation in Wfs1 KO (KO) 
rats’ inferior olive. Representative histological images of IBA1 positive microglia cells 
after 6 months of liraglutide/saline treatment in every treatment group and genotype (a) 
WT Sal, (b) WT Lira, (c) KO Sal, (d) KO Lira. (e) Stereological quantification of IBA1-
positive cells in the inferior olive after 6 months of liraglutide treatment. The data were 
compared using factorial ANOVA followed by Fisher’s LSD tests, ***p < 0.001. The 





































A connection between microglia and Wfs1 has been reported previously, namely, 
hemin-treated microglia induced increased levels of Wfs1, along with increased 
levels of iNOS, TNF-α, HMOX1, NRF2, Xbp-1 and spliced Xbp-1 in mouse 
microglial cell line (Sayeed et al., 2017). Hemin is a toxic, endogenous break-
down product of hemoglobin and partly causes stroke secondary injury, which 
involves microglia-induced inflammatory response (Robinson et al., 2009). This 
suggests that Wfs1 has a role in the activated microglia-induced inflammatory 
response. Moreover, knockdown of Wfs1 in neurons and glial cells resulted in 
premature death and significantly exacerbated behavioural deficits in flies, sug-
gesting that Wfs1 has also an important function in glia cells (Sakakibara et al., 
2018), and therefore, the role of Wfs1 in microglia activation is an important issue 
for future research. 
The ability of liraglutide to enhance cytoprotective phenotypes has been demon-
strated across different experimental neurodegeneration models, such as in animal 
models of stroke (Sato et al., 2013), Alzheimer’s disease (Hansen et al., 2016) and 
Parkinson’s disease (Liu et al., 2015). However, this is the first time that neuro-
inflammation has been described in a Wolfram syndrome animal model (Seppa 
et al., 2019). 
 
 
5.3.3 Wfs1 KO rats have increased neuronal swelling  
Next, the soma volume of individual neurons was measured using the spatial 
rotator. Neuronal volume was increased in all inferior olive subnuclei of Wfs1 
KO rats compared to WT littermates (Figure 16a–d). Neuronal volume increase 
indicates possible neuronal swelling in Wfs1 KO animals. Neuronal swelling is a 
cytopathological response in which extracellular Na+ and other cations enter 
neurons and accumulate intracellularly. This results in an influx of anions and 
water, which in turn results in osmotic expansion of the cell. Additionally, neuronal 
swelling may include glutamate receptor activation and inhibition of Na+/K+–
ATPase (Liang et al., 2007). Axonal swelling has also been shown in Wolfram 
syndrome patients. One Wolfram syndrome patient’s post-mortem study showed 
occasional axonal swelling in the inferior olivary nuclear complex, in the dorsal 
motor nucleus of the vagus, in the medullary and pontine reticular formation and 
in the raphe nuclei (Shannon et al., 1999). In another post-mortem study, Purkinje 
cells showed axonal ballooning (Genís et al., 1997). It has previously been shown 
that there is an increased vulnerability to excitotoxicity-induced neurodegeneration 
in Wfs1 deficient flies (Sakakibara et al., 2018). Therefore, neuronal swelling 
might be induced due to Wolfram syndrome-related neuropathology caused by 
excitotoxicity. Liraglutide treatment decreased neuronal swelling in the medial 
nucleus in Wfs1 KO animals (Figure 16a), and hence, liraglutide treatment might 
have an anti-excitotoxicity effect. Liraglutide’s ability to rescue neuronal cells 
from oxidative stress and glutamate excitotoxicity-induced cell death has also 
been previously shown (Li et al., 2015) and thus it can be suggested that liraglutide 
provides neuroprotection through this mechanism (Seppa et al., 2019). 
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Figure 16. Neuronal volume was increased in Wfs1 KO (KO) animals. Neuronal cell 
volume in (a) medial nucleus, (b) dorsal nucleus, (c) principal nucleus and (d) in all 
inferior olive (IO) nuclei together. (d) In Wfs1 KO (KO Sal) animals, there is an increased 
number of large neurons (1600 µm3 and above, dotted line), as compared to liraglutide-
treated Wfs1 KO animals, indicating that liraglutide treatment prevented neurons from 
swelling. The data were compared using one-way ANOVA followed by Tukey’s HSD 
tests; *p < 0.05, **p < 0.01, ***p < 0.001. The data are presented as the mean ± SEM, 
n = 4–7 per group (Seppa et al., 2019). 
 
 
5.3.4 The total number of neurons in the inferior olive 
Post-mortem neuropathological examinations have revealed neuronal loss in 
Wolfram syndrome patients’ brainstems (Genís et al., 1997; Hilson et al., 2009; 
Shannon et al., 1999), although it is not known when the neuronal loss starts and if 
Wolfram syndrome rats have similar neuronal loss compared to Wolfram syndrome 
patients (Seppa et al., 2019). 
Therefore, to determine if 14-month-old Wfs1 KO animals have inferior olive 
degeneration, stereological quantification of the total number of neurons in the 
inferior olive was performed. Stereology was done under the assumption that the 
volume of the three nuclei of the inferior olive was unchanged between the groups 
(Figure 17 a–d). Thionin staining effectively stained neurons (Figure 17, illustrative 
panel above). The total number of neurons in the inferior olive was estimated in 
three major subnuclei in the inferior olive – in the medial nucleus, dorsal nucleus, 
and principal nucleus – using the optical fractionator (Figure 17). Our results 
indicate that in the dorsal nucleus, there was an increased number of neurons in 
liraglutide-treated KO animals compared to saline-treated Wfs1 KO animals 




























 Figure 17. The total number of neurons in the inferior olive was estimated using the 
optical fractionator. Above, in the illustrative panel, three major subnuclei in the inferior 
olive are visible: the medial nucleus (green line), dorsal nucleus (blue line) and principal 
nucleus (red line). A systematic set of sections, 8 slides per animal, were Thionin stained 
from bregma level –12 until –14.76, delineation of the region of interest (ROI) was 
performed using a 4× objective (images 1– 8), and the counting was performed with a 
60× oil objective (lower right image) using newCAST (Visiopharm, Hoersholm, 
Denmark) software. Volume of the inferior olive (a) medial nucleus; (b) dorsal nucleus; 
(c) principal nucleus; and (d) in all inferior olive (IO) nuclei together. Stereology was 
performed under the assumption that the volume of the three nuclei of the inferior olive 
was unchanged between the groups. Delineation of the region of interest (ROI) was 
performed using a 4× objective, and the ROI volume was calculated using newCAST 
(Visiopharm, Hoersholm, Denmark) software (Seppa et al., 2019).










































































































































Figure 18. After liraglutide treatment, there was an increased number of neurons in Wfs1 
KO (KO) animals’ dorsal nucleus. Stereological quantification of the total number of 
neurons in the inferior olive after 6 months of liraglutide treatment. Total number of 
neurons in the (a) medial nucleus, (b) dorsal nucleus, (c) principal nucleus, and (d) in all 
inferior olive (IO) nuclei together. The data were compared using factorial ANOVA 
followed by Fisher’s LSD tests; *p < 0.05. The data are presented as the mean ± SEM, 
n = 4–8 per group (Seppa et al., 2019). 
 
We found no reduction in the number of neurons in the Wfs1 KO animals 
compared to WT littermates. Probably, the experiment was completed before 
neurodegeneration could occur. The liraglutide treatment protected the inferior 
olive from inflammation and ER stress as it did in the pancreas. However, the 
question remains whether cellular loss follows inflammation and ER-stress in the 
inferior olive as it does in the pancreatic Langerhans islets.  
 
 
5.3.5 Brainstem volume increased with age  
Wolfram syndrome rats have reduced brainstem volume, although it is not known 
when the volume decrease starts (Figure 8a, d). Therefore, magnetic resonance 













































































































changes during liraglutide treatment (Figure 19a). T2-weighted in vivo MRI 
analysis revealed that brainstem volume increased with age in all experimental 
groups, although in Wfs1 KO animals, the increase was smaller (Figure 19b). At 
the age of 14 months, after 6 months of liraglutide treatment, there was no 
decrease in the brainstem volume as we have seen in 15-month-old Wfs1 KO 
animals (Figure 8a, d). Additionally, there was no increase in the EPS volume as 
we have seen in 15-month-old Wfs1 KO animals (Figure 8b, d). The experiment 
probably ended before the changes could occur. However, similarly to our 
previous results (Figure 8h), the ventral surface of the brainstem of Wfs1 KO 
animals appears to be more concave than in WT littermates (Figure 19a). 
Possibly, the concaved brainstem ventral surface may occur prior to volume 
depletion and subsequent degeneration (Seppa et al., 2019).  
 
 
Figure 19. Brainstem volume increased with age in all experimental groups. (a) Re-
presentative T2-weighted MR images of the medulla of saline-treated WT and Wfs1 KO 
(KO), liraglutide-treated WT and Wfs1 KO rats were taken from the level of the inferior 
olive (bregma approx. −12.63 mm). Quantitative MRI analysis of (b) medullary volume 
and (c) extraparenchymal space (EPS) were manually traced by an observer blinded to 
the genotypes of the rats from T2 images using ITK-SNAP software. The volumes of the 
segmented structures were calculated as volume per slice from bregma level −9.48 to 
−15.48 mm. The data were compared using repeated measures ANOVA followed by 
Bonferroni post hoc tests; **p < 0.01, ***p < 0.001. The data are presented as the 
mean ± SEM, n = 6–10 per group (Seppa et al., 2019).  
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5.3.6 Conclusion from Paper III 
Late intervention with liraglutide was able to protect against ER stress in the 
inferior olive. Moreover, it was the first time that microglia and astroglia activation, 
also defined as neuroinflammation, was described in a Wolfram syndrome animal 
model, and liraglutide treatment protected the inferior olive against neuroinflam-
mation. Additionally, liraglutide treatment protected Wolfram syndrome rats from 
neuronal swelling. Altogether, liraglutide had a neuroprotective effect on an aged 
Wolfram syndrome rats.  
 
 
5.4 Paper IV  
Wolfram syndrome is associated with cognitive decline and mood disorders. 
Therefore, our aim was to investigate (i) if liraglutide has a protective effect on 
the hippocampus as we have seen in the pancreas and in the brainstem and (ii) if 
7,8-DHF alone or in combination with liraglutide has a neuroprotective effect on 
the hippocampus. Thus, we took 9-month-old Wolfram syndrome rats and their 
WT littermates and treated them daily with liraglutide, 7,8-DHF or with a 
combination of liraglutide and 7,8-DHF up to the age of 12.5 months (n=47,  
5–8 per group). 
 
 
5.4.1 Cellular stress response in the hippocampus  
Since we have detected ER-stress and inflammation in the pancreas (Figure 3, 
10), medulla (Figure 7) and in the inferior olive (Figure 13), our next aim was to 
investigate the cellular stress response in the hippocampus.  
Indeed, there is also some dysregulation in the cellular stress response in Wfs1 
KO animals’ hippocampus compared to WT control animals. The absence of 
CHOP is associated with apoptosis and impaired memory performance (Chen et 
al., 2012). Here, Chop mRNA levels were downregulated in Wfs1 KO rats com-
pared to WT controls (Figure 20a) (Seppa et al., 2021). 
GRP78 is the key mediator of the UPR pathway (Lee, 2005), and interestingly, 
Grp78 mRNA expression in treatment groups was different between genotypes 
(Figure 20b). In WT animals, 7,8-DHF treatment decreased Grp78 expression, 
while in Wfs1 KO rats, 7,8-DHF had no effect on Grp78 mRNA expression. In 
Wfs1 KO animals treated with liraglutide and co-treated with liraglutide and  
7,8-DHF, Grp78 levels were decreased compared to saline-treated WT and Wfs1 
KO animals.  
Hmox1 is upregulated in response to oxidative stress to provide protection 
(Ryter and Tyrrell, 2000). Hmox1 was elevated in WT animals treated with the 
combination of 7,8-DHF and liraglutide (Figure 20c). Moreover, there was a 
tendency to find decreased Hmox1 levels in liraglutide treatment groups in both 
genotypes (Seppa et al., 2021). 
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It has been shown that TLR2 and TLR4 have opposing functions. TLR2 
deficiency in mice resulted in impaired hippocampal neurogenesis, whereas the 
absence of TLR4 is associated with enhanced proliferation and neuronal dif-
ferentiation (Rolls et al., 2007). Here, hippocampal Tlr2 levels were down-
regulated in Wfs1 KO rats compared to WT control rats (Figure 20d), and in Tlr4 
expression, there was no difference between genotypes. In liraglutide-treated 
Wfs1 KO animals, Tlr4 was upregulated (Figure 20e). KI67 is used as a marker 
for cell proliferation (Gerdes et al., 1983). Ki67 expression was not increased in 
liraglutide-treated Wfs1 KO animals (Figure 21f). Therefore, we cannot confirm 
the association between Tlr4 expression decrease and enhanced proliferation 
(Seppa et al., 2021). 
 
 
Figure 20. Gene expression analyses from 12.5-month-old animals’ hippocampus after 
3.5 months of treatment. (a) Chop, (b) Grp78, (c) Hmox1, (d) Tlr2, (e) Tlr4, (f) Ki67. 
Gene expression data were compared using factorial ANOVA followed by Fisher’s LSD 
tests; * p<0.05; ** p<0.01; *** p<0.001 compared to WT Sal animals and # p<0.05; ## 
p<0.01 compared to KO Sal animals. The data are presented as the mean ± SEM,  
n = 5–8 per group (Seppa et al., 2021). 
 
 
5.4.2 Liraglutide treatment protects against inflammation and  
lateral ventricle enlargement 
Lateral ventricle enlargement is associated with neurodegeneration in Alzheimer’s 
disease (Nestor et al., 2008). In addition, ventricular enlargement has been reported 
in TRL2-deficient mice (Park et al., 2015). Since we saw that TLR2 is down-

































































































































































































































































































































enlargement is also present in Wfs1 KO rats. Therefore, we performed in vivo 
magnetic resonance imaging (MRI) analyses at the beginning of the experiment, 
at the age of 9 months and after 3.5 months of treatment when the animals were 
12 months old (Figure 21a). Lateral ventricle volume was increased over time in 
saline-treated Wfs1 KO animals, which indicates a new symptom of neuro-

























































































LV versus Ip10 in KO Sal animals










































































Figure 21. Wfs1 KO animals have increased volume of lateral ventricles. (a) Re-
presentative MR images of the hippocampus and lateral ventricles of WT and Wfs1 KO 
(KO) animals from every treatment group. Results of quantitative MRI analyses of 
(b) hippocampus and (c) lateral ventricles. Gene expression analyses of the hippocampus 
were performed to measure (d) Ip10 mRNA levels. (e) Positive correlation between 
lateral ventricle volume and Ip10 mRNA expression. Data are analysed with repeated 
measures ANOVA followed by Fisher LSD post hoc test, *p < 0.05 and **p < 0.01 
compared to WT Sal animals, ##p < 0.01, ### p < 0.001 compared to KO Sal animals. 
Data are presented as mean ± SEM, n = 5–8 (Seppa et al., 2021). 
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Mildly dilated lateral ventricles has been also reported in one female Wolfram 
syndrome patient’s post-mortem study (Shannon et al., 1999). Liraglutide, 7,8-
DHF or their combination prevented Wfs1 KO rats from lateral ventricle enlarge-
ment, and thus all treatment combinations had a neuroprotective effect (Figure 
21c). No hippocampal atrophy was accompanied by enlargement of the lateral 
ventricles (Figure 21b). This coincides with patient data, as hippocampal atrophy 
is not detected in Wolfram syndrome patients (Hershey et al., 2012; Hilson et al., 
2009; Lugar et al., 2016). Only in a couple of Wolfram syndrome patients there 
was a tendency for hippocampal volume decrease, but it was not significant 
(Zmyslowska et al., 2014), and therefore, hippocampal atrophy is presumably not 
part of Wolfram syndrome pathology (Seppa et al., 2021). 
Inflammatory marker Ip10 levels were elevated in saline-treated Wfs1 KO 
animals compared to saline-treated WT animals (Figure 21d), and treatment with 
liraglutide, 7,8-DHF or with the combination of liraglutide and 7,8-DHF pre-
vented such an increase of inflammation marker Ip10 in the hippocampus. Thus, 
liraglutide and 7,8-DHF showed strong neuroprotective effects alone and in 
combination in the hippocampus. Additionally, in saline-treated Wfs1 KO 
animals, Ip10 levels and lateral ventricle volume were increased, linear regression 
analyses was performed and a positive correlation was observed between Ip10 
levels and lateral ventricle volume increase (R2 =0.580) (Figure 21e) (Seppa et 
al., 2021). This indicates that lateral ventricle increase can be associated with 
increased inflammation in the hippocampus.  
The protective effect of liraglutide was also seen in the Paper II, in which  
5-month treatment with liraglutide protected Wfs1 KO animals’ pancreatic islets 
from an increase in Ip10 gene expression. Hence, liraglutide anti-inflammatory 




5.4.3 Liraglutide treatment maintained cognitive function 
As cognitive decline correlates with increased volume of the lateral ventricles 
(Carmichael et al., 2007), we performed the Morris water maze experiment to 
evaluate the cognitive abilities of 12-month old Wfs1 KO rats. During probe day, 
Wfs1 KO rats needed significantly more time to reach the platform, and they 
spent less time in the target quadrant compared to saline-treated control animals 
(Figure 22a, b), which indicates cognitive decline in Wfs1 KO animals. Cognitive 
decline is also a described Wolfram syndrome symptom (Chaussenot et al., 2011), 
which additionally shows that the Wfs1 KO rat is a valuable Wolfram syndrome 
model. Treatment with liraglutide, 7,8-DHF or their combination kept the Wfs1 
KO animals’ cognitive capacity similar to the control animals, which reveals an 
impressive neuroprotective effect of these treatments (Seppa et al., 2021). 
12-month-old Wolfram syndrome rats had developed cognitive decline, 
ventricular enlargement, and inflammation in the hippocampus. These symptoms 
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are also the symptoms of Alzheimer’s Disease (Chou et al., 2009; Dubois et al., 
2014; Nestor et al., 2008; Pini et al., 2016; Xia et al., 2000), which suggests a 
similar course of neurodegeneration in both diseases. Therefore, Wolfram 
syndrome studies may also lead to the development of novel treatments options 
for other neurodegenerative diseases (Seppa et al., 2021). 
 
  
Figure 22. Morris water maze experiment results. Morris water maze was performed to 
evaluate Wfs1 KO (KO) rats’ cognition. (a) Time to reach the platform on the probe day, 
(b) time spent in target quadrant on the probe day. Data are analysed with repeated 
measures ANOVA followed by Fisher LSD post hoc test, *p<0.05 compared to WT Sal 
animals, ##p<0.01 compared to KO Sal animals. Data are presented as mean ± SEM, 
n=5–8 (Seppa et al., 2021). 
 
 
5.4.4 Conclusion from Paper IV 
Liraglutide had a protective effect on the hippocampus, as we have seen previously 
in the pancreas and in the inferior olive. Liraglutide treatment protected against 
inflammation in hippocampus and against lateral ventricle enlargement; 
moreover, liraglutide treatment maintained cognitive function. Similarly to 
liraglutide, BDNF mimetic 7,8-DHF also had a neuroprotective effect. 
  































































































Wolfram syndrome is a rare hereditary disorder that is caused by dysfunctional 
WFS1 protein (Inoue et al., 1998; Strom et al., 1998). Wolfram syndrome starts 
with diabetes mellitus followed by optic nerve atrophy and neurodegeneration 
(Barrett et al., 1995). Wolfram syndrome’s first symptom, diabetes mellitus, can 
effectively be controlled with insulin replacement therapy; however, currently 
there is no treatment to stop neurodegeneration. In order to investigate Wolfram 
syndrome caused by WFS1 deficiency, our research group has created the Wfs1 
KO rat (Plaas et al., 2017). The aim of this thesis is to characterize the Wolfram 
syndrome rat model to be able to use it for the evaluation of new treatment 
strategies, with a particular focus on neurodegeneration associated with Wolfram 
syndrome, which has been little studied compared to diabetes mellitus.  
The first paper focused on characterizing the Wfs1 KO rats’ phenotype. As a 
result of the non-functional WFS1 protein, all of the main symptoms of Wolfram 
syndrome were present, such as diabetes mellitus and neurodegeneration, 
including ER stress in the brainstem, increased extraparenchymal area around the 
brainstem, and decreased volume per slice of the brainstem on the level of the 
olive nucleus. Consequently, the symptoms in the Wfs1 KO rat appear to be 
similar to those of Wolfram syndrome patients, and hence, it can be defined as 
the Wolfram syndrome rat and can be used to evaluate new treatment strategies 
(Plaas et al., 2017). 
Drug reproposing involves the use of de-risked compounds, and it is used 
increasingly to treat both common and rare diseases (Pushpakom et al., 2019). In 
recent years, diabetes drugs have been investigated for neuroprotective properties 
because neurodegenerative diseases and diabetes mellitus share common patho-
physiological features, such as cellular stress, inflammation, insulin resistance 
and abnormal protein processing (Salcedo et al., 2012). Thus, in the following 
papers, our aim was to investigate the effect of the antidiabetic drug liraglutide 
on Wolfram syndrome symptoms. 
The second paper focused on the diabetic phenotype. GLP-1 receptor agonists 
are used for the treatment of type 2 diabetes because they increase glucose-
dependent insulin release from beta cells and thereby reduce postprandial glucose 
levels. To investigate if liraglutide has a preventive effect on Wolfram syndrome 
rats’ diabetic phenotype, we started chronic treatment before the onset of disease 
symptoms, at the age of 2 months, and the treatment lasted for 5 months. Indeed, 
the results indicate that early treatment with liraglutide prevented the develop-
ment of diabetes mellitus in Wfs1 KO animals (Toots et al., 2018). 
Next, in the third paper, our aim was to investigate whether liraglutide could 
also have a therapeutic effect on brainstem neurodegeneration. It is known that 
GLP-1 receptors are also expressed in neurons, astrocytes and in microglia cells; 
hence, we hypothesized that liraglutide could also have a neuroprotective effect 
in Wolfram syndrome. In order to mimic human patients who are diagnosed with 
Wolfram syndrome after the development of diabetes, we started treatment in 9-
month-old animals who had already developed glucose intolerance, and the 
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treatment lasted for 6 months. Our results suggest that, in Wolfram syndrome 
rats, neuroinflammation proceeds to neuronal damage, and additionally, Wolfram 
syndrome rats develop ER stress and neuronal swelling in the inferior olive. 6-
month liraglutide treatment reduced neuroinflammation, neuronal swelling and 
ER stress in the inferior olive of Wolfram syndrome rats. Hence, this paper 
investigated for the first time liraglutide’s neuroprotective effect in connection 
with Wolfram syndrome.  
The fourth paper studied the neuronal phenotype further and evaluated for the 
first time the effect of BDNF mimetic 7,8-DHF on an aged Wolfram syndrome 
rat hippocampus. 9-month-old Wolfram syndrome rats and wild-type (WT) control 
animals were treated for 3.5 months with liraglutide, 7,8-DHF or with a combi-
nation of liraglutide and 7,8-DHF. We found that liraglutide, 7,8-DHF and their 
co-treatment all prevented lateral ventricle enlargement, improved learning in the 
Morris water maze and reduced inflammation in the hippocampus. Thus, 
liraglutide, 7,8-DHF and their co-treatment could potentially be used as a 
therapeutic intervention to induce neuroprotection (Seppa et al., 2021).  
Altogether, chronic treatment with liraglutide protected Wfs1 KO rats against 
development of glucose intolerance and was neuroprotective in the brainstem and 
in the hippocampus. Additionally, BDNF mimetic 7,8-DHF had a similar neuro-
protective effect compared to liraglutide.  
This thesis systematically characterized the Wolfram syndrome rat, for which 
the phenotype correlates with Wolfram syndrome patients. The fastest way to get 
a new treatment in practice is drug repurposing, as the side effects and safety are 
already known. The current thesis demonstrates a significant therapeutic effect of 
the GLP-1 receptor agonist liraglutide to prevent or slow the onset of symptoms 
of Wolfram syndrome in the Wolfram syndrome rat model. Therefore, early diag-
nosis and treatment with GLP-1 receptor agonists may also prove to be a pro-
mising treatment option for Wolfram syndrome patients by significantly improving 
their quality of life. Thus, such a systematic approach could also be used to study 
other rare diseases. 
Further investigations will continue in humans. Inspired by preclinical studies 
with liraglutide, researchers from St. Louis, MO, USA have initiated a liraglutide 
clinical trial (https://thesnowfoundation.org/clinical-trials/). This clinical trial 
will clarify if liraglutide has a similar preventive effect on the development of 




I Wfs1 KO rats developed both diabetes mellitus and neurodegeneration. The 
results demonstrate that ER stress occurs prior to cellular loss in the pancreas 
and to decreases in the brainstem volume of Wfs1 KO rats. 
II Liraglutide treatment protected the Langerhans islets from ER stress and 
thus maintained Langerhans islets’ cellular function and mass and protected 
Wfs1 KO rats against developing glucose intolerance. 
III Liraglutide treatment protected Wfs1 KO rats’ inferior olive against ER 
stress, neuronal swelling and neuroinflammation, as measured by an increased 
number of IBA positive microglia cells and GFAP positive astroglia cells. 
Thereby, it had a neuroprotective effect. 
IV Liraglutide treatment protected Wfs1 KO rats’ hippocampus against inflam-
mation, prevented ventricular enlargement and maintained cognitive function. 
Similarly to liraglutide, 7,8-DHF alone and in combination with liraglutide 
protected the hippocampus against inflammation and maintained cognitive 





SUMMARY IN ESTONIAN 
Wolframi sündroom on haruldane autosomaalse retsessiivse pärandumismustriga 
haigus, mida põhjustab WFS1 geeni poolt kodeeritud Wolframiini valgu düsfunkt-
sioon. Wolframi sündroomi esimene sümptom on insuliinist sõltuv diabeet ning 
sellele järgnevad nägemisnärvi atroofia, magediabeet ja neuroloogilised kompli-
katsioonid. Insuliinist sõltuv diabeet on kontrollitav insuliini asendusraviga, seega 
on Wolframi sündroomiga patsientidele enim muret valmistav neurodegenerat-
sioon, millele puudub ravi. Seepärast on oluline välja töötada neuroprotektiivseid 
ravimeetodeid, mis oleksid võimelised aeglustama haiguse kulgu ja seeläbi 
pikendama Wolframi sündroomiga patsientide eluiga. 
Wolframiini valgu düsfunktsioonist põhjustatud Wolframi sündroomi uuri-
miseks on meie uurimisrühm loonud Wfs1 KO roti, kelle Wfs1 geeni viies kodeeriv 
ekson on deleteeritud. Antud doktoritöö eesmärgiks oli iseloomustada Wfs1 KO 
roti fenotüüpi, eesmärgiga kasutada seda uute ravistrateegiate väljatöötamisel. 
Antud töös pöörati erilist tähelepanu Wolframi sündroomiga seotud neuro-
degeneratsioonile, mida on insuliinist sõltuva diabeediga võrreldes vähe uuritud. 
Esimene uuring keskendus Wfs1 KO rottide fenotüübi iseloomustamisele. 
Mittefunktsionaalse Wolframiini valgu tagajärjel kujunesid Wfs1 KO rotil kõik 
Wolframi sündroomi peamised sümptomid nagu insuliinist sõltuv diabeet ja 
neurodegeneratsioon, sealhulgas ajutüves esinev endoplasmaatilise retiikulumi 
(ER)-stress, ajutüve ümbritseva ekstraparenhümaalse ala pindala suurenemine ja 
ajutüve ruumala vähenemine oliivtuumade tasandil. Seega näib, et Wfs1 KO roti 
sümptomid on sarnased Wolframi sündroomiga patsientide omadega ja seetõttu 
saab Wfs1 KO rotti pidada Wolframi sündroomi loommudeliks ja seda saab kasu-
tada uute ravistrateegiate hindamiseks. 
Kiireim viis uue praktikas kasutatava ravi saamiseks on olemasolevatele ravi-
mitele uue näidustuse leidmine, kuna kõrvalmõjud ja ohutus on juba teada. Antud 
lähenemist kasutatakse üha sagedamini nii erinevate haiguste kui ka harvikhaiguste 
raviks. Viimastel aastatel on uuritud diabeediravimite neuroprotektiivseid oma-
dusi, kuna neurodegeneratiivsetel haigustel ja diabeedil on ühised patofüsioloogi-
lised tunnused nagu rakustress, põletik, insuliiniresistentsus ja valkude voltumise 
häired. Sellest tulenevalt oli meie eesmärk uurida diabeediravimi liraglutiidi mõju 
Wolframi sündroomi põhisümptomitele: insuliinist sõltuvale diabeedile ja neuro-
degeneratsioonile.  
Teine uuring keskendus liraglutiidi mõju uurimisele insuliinist sõltuva diabeedi 
fenotüübile Wolframi sündroomi rottidel. GLP-1 retseptori agoniste kasutatakse 
teist tüüpi diabeedi raviks, kuna need suurendavad glükoosist sõltuvat insuliini 
vabanemist beeta-rakkudest ja vähendavad seeläbi söögijärgset glükoositaset. Et 
uurida, kas liraglutiidil on ennetav toime Wolframi sündroomi rottidel esineva 
insuliinist sõltuva diabeedi väljakujunemisele, alustasime kroonilist ravi enne 
haigusnähtude ilmnemist kui loomad olid 2 kuu vanused ning ravi kestis 5 kuud. 
Tulemused näitasid, et varajane ravi liraglutiidiga hoidis tõepoolest ära diabeedi 
tekke Wolframi sündroomi rottidel. 
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Kolmanda uuringu eesmärk oli uurida, kas liraglutiidil võib olla terapeutiline 
toime ka ajutüve neurodegeneratsioonile. On teada, et GLP-1 retseptoreid ekspres-
seeritakse neuronites, astrotsüütides ja mikrogliia rakkudes, mistõttu oli meie 
hüpoteesiks, et liraglutiidil võib olla Wolframi sündroomi korral ka neuroprotek-
tiivne toime. Wolframi sündroomiga patsientide jäljendamiseks, kellel diagnoosi-
takse Wolframi sündroom üldjuhul pärast diabeedi tekkimist, alustasime liraglu-
tiidi ravi 9-kuustel loomadel, kellel oli juba tekkinud glükoositalumatus ja ravi 
kestis 6 kuud. Meie tulemused näitavad, et Wolframi sündroomi rottidel eelneb 
neuropõletik neurodegeneratsioonile ja lisaks tekivad Wolframi sündroomiga 
rottidel oliivtuumades ER stress ja neuronite ruumala suurenemine. 6-kuu pikkune 
liraglutiidi ravi vähendas Wolframi sündroomi rottide oliivtuumades neuropõle-
tikku, neuronite ruumala suurenemist ja ER-stressi. Seega näidati selles uurimis-
töös esmakordselt liraglutiidi neuroprotektiivset toimet Wolframi sündroomi 
loommudelis. 
Neljas uuring keskendus neurodegeneratsioonile ning esmakordselt hinnati 
BDNF-i mimeetiku 7,8-dihüdroksüflavooni (7,8-DHF) toimet vananenud 
Wolframi sündroomi rottide hipokampusele. 9 kuu vanuseid Wolframi sünd-
roomi rotte ja nende metsiktüüpi (WT) kontroll-loomi raviti 3,5 kuud liraglutiidi, 
7,8-DHF või liraglutiidi ja 7,8-DHF kombinatsiooniga. Leidsime, et nii liraglutiid, 
7,8-DHF kui ka nende samaaegne ravi hoidis ära Wolframi sündroomi rottide 
külgvatsakeste ruumala suurenemise, parandas õppimist Morrise veelabürindis ja 
vähendas põletikku hipokampuses. Seega võiks liraglutiidi, 7,8-DHF ja nende 
koos kasutamist potentsiaalselt tarvitada neuroprotektiivse ravina. 
Kokkuvõttes kaitses krooniline ravi liraglutiidiga Wfs1 KO rotte glükoosi-
talumatuse tekke eest ning oli neuroprotektiivne ajutüves ja hipokampuses. Lisaks 
oli BDNF-i mimeetikul 7,8-DHF-l liraglutiidiga sarnane neuroprotektiivne toime. 
Antud doktoritöös kirjeldati süstemaatiliselt Wolframi sündroomi rotte, kelle 
fenotüüp korreleerub Wolframi sündroomiga patsientidega. Sellisel loommudelil 
saadud tulemustel on head eeldused olla reprodutseeritavad inimkatsetes ning 
samuti on hea tõenäosus sellisel loommudelil tõestatud ravi edukaks siirdamiseks 
kliinilisse meditsiini. Käesolev doktoritöö näitas GLP-1 retseptori agonisti liraglu-
tiidi olulist terapeutilist toimet Wolframi sündroomi loommudelis Wolframi 
sündroomi sümptomite tekke ärahoidmisel või aeglustamisel. Seetõttu võib vara-
jane diagnoosimine ja ravi GLP-1 retseptori agonistidega osutuda paljutõotavaks 
ravivõimaluseks ka Wolframi sündroomiga patsientidele, parandades oluliselt 
nende elukvaliteeti. Lisaks saaks sellist süstemaatilist lähenemist kasutada ka 
teiste harvikhaiguste uurimiseks. 
Lähtudes liraglutiidi prekliinilisetst uuringutest on algatatud liraglutiidi 
kliiniline uuring (https://thesnowfoundation.org/clinical-trials/). See kliiniline 
uuring annab selgust, kas liraglutiidil on sarnane ennetav toime diabeedi arengule 
ja neurodegeneratsioonile nagu on kirjeldatud Wolframi sündroomi rottidel. 
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